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Abstract
Meptazinol, dl-rn (3 ethylhexahydro-1-methyl-1H-azepin-3-yl) 
phenol hydrochloride is a new analgesic agent, which from animal 
studies appears to have a low addiction liability. By contrast however, 
the desmethyl derivative, although still a potent analgesic was shown 
to have a much greater addiction potential.
Metabolic studies using a novel dual labelling approach showed 
no evidence for the formation of normeptazinol in animals or man. The 
major metabolic pathway seen in all the species so far investigated 
involves rapid conjugation with glucuronic acid. A minor metabolite 
found only in the urine of monkeys and man has been tentatively identified 
as 6-ethyl-6-(m hydroxyphenyl)-1-methy!hexahydro-azepin-(2H)-2-one 
This metabolite was shown to be biologically inactive.
Pharmacological studies showed meptazinol to be considerably less 
potent after oral as compared to parenteral administration. A good corre­
lation between the intensity of the drug's biological effects and plasma
mice
levels of the compound was demonstrated in rats^and monkeys. Oral 
administration of the drug was shown to produce much lower plasma levels of 
the free drug than parenteral dosage. This did not appear to be due to 
incomplete absorption since the drug was efficiently absorbed in all these 
species. However the rate of absorption was considerably slower in monkeys 
and man, an effect which was shown to cause more extensive first pass 
conjugation of the drug in these species. This slower absorption was at
least partly due to the longer gastric emptying time in these species. Tn 
addition, studies in the monkey showed the drug to have a marked retarding 
action on stomach emptying, an effect not seen in the rat.
Rectal administration of the drug has been shown to provide a 
means of circumventing the problem of extensive first pass metabolism and 
effectively increasing the drug's potency. In man plasma levels of the drug 
resulting from rectal dosage were five to ten times higher than when the 
same dose was given orally.
Preface
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In recent years with the increasing -availability of radio­
tracers and more sophisticated analytical equipment, drug metabolism 
studies have been able to make an increasingly greater contribution 
to the development of new therapeutic agents. Using radio-tagged 
drugs, the elucidation of the metabolic and pharmacokinetic profile of 
a new drug can now be performed sufficiently rapidly to enable these 
results to be used* in the design of future pharmacological and 
toxicological studies.
For example the selection of the most appropriate animal 
species for extended pharmacological and toxicological studies is now 
beginning to be based on the results of comparative metabolic studies 
in animals and man. The use of a species in which the kinetics and 
metabolism of the drug are similar to man will enable a safer' extra­
polation of animal toxicity data to man.
Absorption studies on a compound intended for oral administra­
tion are obviously necessary for, in the event of incomplete absorption, 
blood levels and probably therefore biological response, may be erratic. 
Furthermore the drug must be shown to be well absorbed in the species 
chosen for toxicity testing otherwise any absence of toxic effect could 
be ascribed to poor absorption. In the field of drug formulation the 
demonstration of good in vivo, as well as, in vitro bioavailability is 
obviously very worthwhile before undertaking costly long term stability 
studies on the formulation.
Studies on the tissue distribution of a new drug may lend some 
insight into the reasons for a toxicological response in a particular 
organ. In teratological studies too, tissue distribution studies in 
the pregnant animal should establish that the compound actually reaches 
the foetus.
Studies on the.routes and rates of excretion of a new drug 
are also important. A drug having a very long half life may require 
several weeks of daily administration.before a steady state body level 
of the drug is achieved, clearly a decided disadvantage. Furthermore 
any unexpected toxic reaction to such a drug is likely to persist for 
a relatively long time. By contrast a drug having a very short half 
life may need to be given in relatively high doses in order to prolong 
the dosage interval. If such a compound has a poor therapeutic index
toxic effects may become apparent when the drug is given in this way.
/
This illustrates the significance of excretion studies which 
should reveal whether the drug has an acceptable half life.
Studies on the biotransformation of the compound may reveal 
the existence of pharmacologically active metabolites. Such metabolites 
may have an improved profile of action over the parent drug. For ' 
example, oxazepam, a metabolite of the anxiolytic agent diazepam, was 
found to retain the tranquillizing properties of the parent drug but 
produced less sedation. Similarly, oxyphenbutazone* a metabolite of the 
anti-rheumatic agent, phenylbutazone retained the pharmacological activity 
of the parent drug but was found to have fewer side effects.
The demonstration of a correlation between biological activity
and plasma levels of either the parent drug or a metabolite has considerable
importance. With some psychiatric conditions it is not easy to quantify
/>
patient response to a drug and it may therefore be difficult to establish 
the most appropriate dosage regimen. Knowledge of the existence of a 
correlation between intensity of the drug's effects and its plasma 
concentration, and of the drug's kinetic behaviour in man should enable 
a suitable dosage regimen to be designed.
Thus from a study of the absorption, distribution biotrans­
formation and excretion of new drug candidates, a better understanding of 
the factors controlling the drug's actions should be obtained. From
this understanding it may be possible to beneficially modify the drug's 
behaviour. Suitable modifications to the drug formulation or drug 
structure may enable improvements to be made in the absorption, distribu­
tion and excretion of the compound. The following thesis is intended 
to demonstrate the utility of such metabolic studies in’ the development 
of a new analgesic drug.
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GENERAL INTRODUCTION
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Some historical background to the emergence of morphine as a 
major pain killing drug is presented. In the light of the drug's 
undesirable side effects the need for a new potent non-addictive 
analgesic is discussed. Some of the more widely used screening pro­
cedures used to identify such compounds are described together with an 
appraisal of their limitations. The current biochemical theories on 
the mechanism by which analgesics elicit their effects are reviewed.
The chronological development of drug structures which eventually led to the
synthesis of the meptazinol series is described. In view of the observation
that normeptazinol (a potential metabolite of the drug) has a higher addictive
liability than meptazinol itself, the importance of metabolic studies to
determine the extent of normeptazinol formation in various species is
discussed. Species differences and dosage route dependent differences in
the drug's biological potency are described together with some comment on*
the usefulness of drug metabolism studies in attempting to understand these 
observations.
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Historical Background
Although pain is a universal experience of mankind it defies 
definition. Its subjective nature means that we can only make state­
ments about what features are associated with it rather than what is 
actually meant by the pain experience. Thus having said that it is 
different from other sensations that it is the opposite of pleasure, 
what kind's there are (sharp, dull, pricking, cutting, burning) and what 
stimuli cause it (extreme heat, cold, pressure, electric shock etc.) 
we have still failed to satisfactorily define what- is meant by the pain 
sensation. Nevertheless nobody would deny that pain is real and its 
relief is probably one of the most important of all medical goals.
In some cases it is possible to remove the cause of the pain 
and thereby remove the pain sensation. In many other instances relief 
from pain may be all that can be provided. In all cases, rapid sympto­
matic relief from pain is wanted and drugs which can provide it - called 
analgesics from the Greek meaning without pain - are amongst the most 
sought after medicines.
The ability of the dried exudate of the opium poppy, Papaver 
somniferium, to relieve pain had been discovered by the time of the 
earliest written records. -Early physicians formed a regard amounting 
to veneration for opium's almost miraculous power to "lull all pain 
and anger and bring relief to every sorrow".
However it was not until 1803 that Friedrich Sertilrner first
described the isolation of the active principle of opium, morphine, so
named after Morpheus, the god of sleep. This subsequently became
generally available in pure form to the medical profession as a result
*
of the work of William Gregory. In 1925 Robinson & Gulland reported 
that they had elucidated the chemical structure of morphine.
(/w)
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MORPHINE
Although morphine still holds first place in the world as a 
major painkiller, it has many undesirable side effects. With daily, 
administration tolerance to the analgesic actions of morphine quickly
0
develops and the dose needs to be progressively increased to produce
iI
the required effect. Tolerance is closely associated with addiction 
which is the most serious limitation to the clinical use of morphine. 
Addiction involves both physical and psychological dependence on the 
drug. It is in this sense that the term narcotic is used to describe' 
such analgesics. Respiratory depression is another undesirable effect 
of morphine. In man respiration is depressed by doses which are below 
the narcotic threshold and this respiratory depressant effect with high 
doses is the major cause of death. Morphine has a retarding action 
upon the digestive system and small doses produce constipation. Its 
effect on the urinary bladder gives rise to urinary urgency but urination 
is more difficult. Urine retention is observed even with therapeutic 
doses. Morphine also frequently gives rise to nausea and vomiting.
The absorption of the drug from the gastro-intestinal tract is reputedly 
poor being ascribed to its relatively high pKa value^ and the respective 
aqueous and lipid solubilities of the ionized and nonionized forms.
Thus over the last forty years an intensive search has been 
made for a new analgesic devoid of these undesired side effects of 
morphine. More recently it has been observed that some compounds will 
antagonize the effects of morphine, i.e. they will precipitate abstinence 
symptoms in addicts receiving morphine, and yet these compounds may 
themselves possess analgesic activity. In addition this, antagonistic
effect seems to be indicative of a lack of addictiveness of these 
compounds. A number of compounds have been shown to be potent narcotic 
antagonists but with one or two exceptions none have been found to be 
useful analgesics. The classical narcotic antagonist nalorphine 
produces hallucogenic symptoms in man making it unsuitable for clinical 
use as an analgesic. Nevertheless the search for narcotic antagonists 
possessing analgesic activity continues.
Pharmacological screening procedures for potential analgesics
The synthesis of new potential analgesics must be accompanied 
by their pharmacological appraisal so that only those that are effective 
pain killers, free of addictive properties and relatively non-toxic are 
selected for further study in humans.
Animals can be made to give.a response to certain stimuli 
which are known to produce painful sensations in humans. Such stimuli 
include the application of heat, pressure, electric shocks or the 
administration of substances such as acetyl choline, bradykinin or 
phenylquinone. The animals response usually takes the form of a flight 
reaction or a squeak which may be interpreted as indicating that the 
animal is suffering pain.
The multiplicity of test procedures described in the literature 
suggest that no ideal test has yet been found. One of the most important 
facets of any method is its predictive value in man.^ The majority of 
screening procedures currently employed appear to be insensitive towards 
the narcotic antagonist analgesics which, because of their potentially 
low addictive liability, are probably the most sought after compounds.
Analgesic screening tests using a thermal stimulus
Initially the widely used rat tail flick test (in which the 
response time for a rat to flick its tail away from a noxious stimulus 
such as heat is measured) was generally highly predictive of clinical 
analgesic activity but failed to select the narcotic antagonists which 
are also capable of relieving pain in man. In 1969 Gray et al 
succeeded in refining this test such that the analgesic action of the 
non-narcotic pentozocine could be detected. The original failure of the 
- method was apparently due to the use of a stimulus intensity which was 
too severe. However, even modified as described the method still appears 
to lack general utility for the detection of the analgesic action of 
narcotic antagonists.
Another widely used screening procedure for potential analgesic 
drugs is the hot plate test in which the response of an animal placed on 
a plate heated to approximately 50° is observed.
The sensitivity of this method for narcotic analgesics compares 
favourably with the tail flick test but again the test is insensitive 
towards the non-narcotics. Indeed the analgesic activity of 
aspirin given to rats at 20^ value could not be demonstrated using
this technique (Lim & Guzman,1968).
Analgesic screening tests using an electrical stimulus
The use of electrical shock for producing pain in man and 
nociceptive responses in animals has given rise to many difficulties 
and inconsistencies. Beecher (1957) has reviewed these critically and 
he concludes that while electrical shock is easy to apply, it is most 
difficult to control for even if voltage and amperage are known, bio­
logical tissues offer impedance which cannot be controlled.
In 1964 Weiss & Laties, described a shock titration procedure 
for evaluating potential analgesics in the monkey. The animals were 
trained to press a lever to step down a constantly and regularly 
increasing shock intensity which they would then maintain at a 
relatively constant level. This tolerated level is raised by morphine 
and other agents. Furthermore the potent narcotic antagonist cycla- 
zocine was active in this test and its potency relative to morphine 
paralleled that seen in- man.• However.the classical narcotic antagonist 
nalophine was apparently devoid of activity in this test. As a general screening 
procedure the technique has a number of disadvantages not least of which 
is the time taken in training animals and the possibility that they may 
become drug dependent as a result of testing potentially addictive 
analgesics. .
Analgesic screening test's using chemical agents as the stimuli
The writhing response produced by intraperitoneal injection 
of agents such as phenyl p benzoquinone, bradykinin, or acetyl choline 
forms the basis of a screening procedure capable of detecting 
the non-narcotic analgesics. Lim and colleagues in 1964 using brady- . 
kinin-induced visceral pain in dogs demonstrated the activity of the non­
narcotic analgesic pentazocine in this test. Later, Blane, (1967) 
reported that the algesic- effects of intra-arterially administered 
bradykinin to the rat could be blocked by nalorphine or pentazocine.
However the test is not without its critics and Archer & Pierson (1966) 
have suggested that it is more indicative of central muscle relaxant 
activity than analgesic action.
Limitations of experimentally induced pain for evaluating analgesics in man 
The various test procedures discussed above are just some of 
the more widely used techniques for evaluating potential analgesics.
Most of them have also been applied, with suitable modification to the 
assessment of analgesics in man. However it is questionable whether any 
of the noxious stimuli used in these tests produces anything resembling
pathological pain in human beings, the relief of which is the object 
of the investigation. Furthermore these experimental situations lack 
the psychological or anxiety component seen in pathological pain in man. 
For example if pain were merely a response to a stimulus from a wound 
one might expect that a severe wound would always produce pain and that 
the intensity of the pain would be related to the severity of the 
stimulus which caused it. Beecher (1946 & 1956) has shown that in men 
wounded in battle, this was not the case. He found that 75%> of the 
seriously wounded did not need medication or even refused it when offered.
I
The degree of pain was not related to the severity of the wound. A 
similar blocking of pain perception has often been seen in athletes 
suffering injuries during the excitement of competition.
On the other hand, post-operative patients with incisions 
similar to those of the wounded soldiers usually complain of severe pain 
and need analgesic medication. Though the conditions of the wounded 
tissue may be similar in the two cases, the response to the stimulus is 
altered by the psychic state.
The influence of the psychological or anxiety component has 
also been shown in experiental situations illustrated by the now classical 
studies of Hill and his colleagues (1952). They were able to show a 
significantly greater response to an electrical stimulus when administered 
to volunteers under an anxiety generating situation compared to when the 
same stimulus was given in a anxiety allaying environment..
Thus in view of the significance of the anxiety component of 
pain many investigators believe that meaningful assessment of potential 
analgesics can only be made in patients suffering from pathological pain.
Although it is desirable to study potential analgesics in 
the clinical situation such investigations are-not without their 
difficulties and problems. Firstly pain is a subjective response 
which makes its quantitative assessment in a comparative sense 
difficult. Crossover studies of drug and placebo in patients suffering 
severe pain pose moral as well as practical problems. In post-operative 
and post-partum situations the intensity of pain is continually dimini­
shing which presents practical difficulties to carrying out multiple 
studies. For this reason patients suffering chronic pain such as cancer 
patients are more suitable for the assessment of new analgesics. How­
ever such patients by the nature of their illness, present further 
problems arising from possible renal or hepatic impairment and the ■ 
consequential effects on drug elimination.
Importance and assessment of addictive.liability of new analgesics
By far the greatest limitation to the use of morphine and its 
narcotic surrogates as analgesics is their high physical and psychological 
dependence liability. Thus in the search for useful new analgesics an 
assessment of their addictive liability usually closely follows the 
evaluation of their pain relieving properties.
The observation of a link between opioid antagonist activity 
and low dependence liability has enabled the rapid determination of the 
addiction potential of candidate analgesic drugs. Thus the precipitation 
of morphine withdrawal symptoms following administration of a new .analgesic 
compound to morphine addicted animals is indicative of a low addictive liability. 
Since tolerance and addiction liability are also closely linked the 
development of tolerance may give an indication of the drugs addictive 
liability. Alleviation of such morphine withdrawal symptoms as weight 
loss, increased defecation by a drug candidate would suggest- the 
new compound to be potentially addictive.
V - /  \s
Useful though these tests may be, the design of reliable, 
meaningful laboratory screening procedures both for identifying potential 
analgesics and for assessing their addiction liability must be based on an 
understanding of the biochemical mechanisms involved. ;
Theories on the mechanism of action of analgesic drugs
In 1952 Beckett pointed out that theories regarding the mode 
of action of the potent analgesics were highly speculative and that "a 
clear picture .... .is as yet a distant goal despite the multitudinous 
array of facts which have been collected!" Despite twenty years of 
further research the mechanism of action of these drugs is still unclear.
The analgesic receptor site(s)
Potent analgesic drugs act centrally by reversible binding to 
a 'receptor site'. An analgesic receptor may be assumed to be a con­
figuration of atoms .either in the cellular membrane or within the cell, 
and the analgesic drug is thought to. complement this structure. Some of 
the physical and chemical properties which such a binding site might 
possess have been postulated by Beckett* (1956a and 1962) and Beckett et al 
(1996b & 1956c) These have been critically discussed by others, more 
recently by Mellett & Woods (1963)- ^ e  receptor is presumed to be a 
charged anionic site with dimensions of the order of 6.5 x 8.5 ^
separated from a flat surface by a cavity (See Fig. 1.) The aromatic portion of the
drug molecule is postulated to be attracted to the flat surface by Van der
/>
Waals' forces. The basic group of the drug is attracted to the anionic 
site, while the cavity provides a third dimension for additional attraction.
Until very recently the exact anatomical localization of these 
sites was unknown. However in the Spring of 1973,Pert & Snyder,announced 
the biochemical demonstration of a receptor in nervous tissue which binds 
opiates with stereospecific selectivity and with affinities paralleling 
their pharmacological potencies. Opiate receptor binding seems to be 
restricted to membrane fractions in nervous tissue. In October 1973
Fig. 1.
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rKuhar, Per.t & Snyder described detailed mapping of the concentration of 
opiate binding sites in both human and monkey brains. They discovered 
striking regional variation in binding-to brain with receptor concentra­
tions varying more than thirtyfold between highest and lowest areas. The 
regions high in opiate binding sites all lie within the limbic system.. Bindi: 
is greatest within the anterior amygdala, uniformly high throughout the 
hypothalamus and high in medial but not in lateral thalamus. Frontal 
cortex areas show moderate binding of opiates, but little is found else­
where in the cerebrum.
Interaction between analgesics and their receptor sites
In 1956 Axelrod drew attention to certain features common both 
to the enzymes in rat liver which N-demethylate analgesics and to the 
receptor sites proposed for these drugs. They interact with the same 
substrate; they show, in some cases, similar degrees of specificity and 
they have actions that are inhibited by nalorphine.
In 1956, Becketb et al advanced a hypothesis regarding the inter­
action of analgesic drugs and their receptor sites in the central nervous 
system. They postulated that formation of a drug-receptor complex by 
itself does not produce an analgesic effect but oxidative dealkylation must 
first occur on the receptor surface. Release of the N-.de alkylated 
derivative on the receptor surface then produces the analgesic response.
A number of observations would seem to support Beckett’s 
hypothesis, Firstly N-dealkylation in the liver, at least, has been shown
f*
to occur with almost all narcotic analgesics studied .(see Way & Adler 1960, 
Way & Adler 1962 and Way 1968). Deuteration of the N methyl group of 
morphine causes a reduction in both analgesic potency and rate of in vitro 
demethylation by liver preparations (Elison et al 1961), a finding in accord 
with, but not proving, a relationship between receptor site N-demethylation 
and analgesic action. . Another interesting observation is that of Axelrod 
(1956) who noted that chronic administration of morphine to rats results 
in a profound reduction in the ability of liver enzyme preparations from
these animals ;to N-dealkylate morphine, nalorphine, hydromorphine and
I '
pethidine. ihese animals showed a diminution of analgesic response to
a test dose of morphine. Further, analgesic response and hepatic N —
i
demethylation showed parallel changes during antagonism with nalorphine.
In reviewing the evidence for the involvement of N~demethylation 
in the mechanism of analgesia,Way & Adler (1962) and . ,  (1968) appear 
to have found a number of anomalies. Firstly nalorphine, a weaker 
analgesic than morphine, is more rapidly N-demethylated to normorphine 
than morphine itself. It should however be emphasized that this data 
relates to the liver and no similar studies have yet been reported using 
receptor site N^demethylase.
While the apparent anomaly of the lower analgesic potency of 
desalkyl analgesics compared to their methylated, congeners could conceivably 
be explained by their relatively poor ability to enter the CNS, it is 
interesting that these compounds are more toxic (which is presumably another 
centrally mediated effect) than their methylated congeners. (Miller & 
Anderson, 195^)«
The early work of Axelrod (1956) in demonstrating a parallel 
decrease in N-demethylation and analgesic activity after chronic admini­
stration of morphine to rats was not substantiated by the work of Adler 
(1967) in mice, who failed to find any decrease in N-demethylating activity 
in mice made tolerant to morphine.
Thus the role of N-demethylation in analgesia is at present 
equivocal basically due to the lack of information on N-demethylation at the 
receptor site. However direct proof for or against Beckett’s hypothesis 
may not be far away in view of the recent isolation of the opiate receptor 
binding sites.
Consequences of drug receptor interaction
Analgesic drugs have been shown to affect many biochemical systems 
but the importance of these actions in actually eliciting the analgesic 
response is not well understood. Thus inhibition of cholinesterase, a 
prominent property of some morphine-like compounds and morphine antagonists 
was at one time widely regarded as a possible biochemical basis for 
analgesia, but numerous studies have failed to establish a relationship 
between anticholinesterase activity and analgesia in a variety of chemical 
structures (Winter et al 196^)-
Biogenic amines, including adrenaline, noradrenaline, dopamine 
and 5 hydroxytryptamine.have been widely studied as potential mediators of 
analgesia. Several authors have reported that analgesia produced by 
sympathomimetic amines and analgesic compounds affect brain levels of 
catecholamines. Reserpine has been shown to inhibit the effects of 
morphine,(Winter,1968.) This has been cited as evidence that morphine 
analgesia is mediated by noradrenaline, since reserpine is known to deplete 
brain noradrenaline. However Rudzik & Mennear (1965) found that other 
amine depleting agents such as ct-methyl-DOPA and a-methyl-m.r-tyrosine 
failed to affect morphine analgesia in mice.
Another possible mechanism to explain the action of potent
analgesics is suggested by the work of'Kakunga et al (1966). ' They found
/>
that calcium ions injected in modest doses intracisternally or in larger
doses subcutaneously or intraperitoneally markedly reduced the analgesic
effectiveness of morphine. The inhibition was equally pronounced whether 
++
the Ca was given v/ith the morphine or after the morphine effect was fully
established. Chelating agents such as EDTA reversed the Ca++ effect
++
or if given without Ca they enhanced the action of morphine. The 
effect was specific. It was not shared by divalent ions other than 
calcium. Some of these findings have been confirmed by Nutt(l968).
These observations are perhaps especially significant ,since
Several other biochemical systems are reported to be effected 
by analgesic drugs {see Clouet (197*0 for a comprehensive review) but despite 
this multitudinous array of facts no clear pattern inter-relating these 
effects has yet emerged and the actual biochemical mechanism of analgesia 
still remains unknown.
Although this incomplete understanding of the biochemical 
mechanism of analgesia has prevented the design of more sophisticated 
screening procedures, several useful analgesics have been discovered using 
the relatively crude procedures described earlier.
Sequence of events leading to the development of meptazinol
In the late 1930's a German chemist/pharmacologist team, Eisleb
& Schaumann (1939) were looking-for a spasmolytic substitute for atropine.
Among the compounds they studied was ethyl-1-methyl-A-phenyl piperidine-A-
carboxylate later known as pethidine or meperidine. Although it was not a
successful spasmolytic agent, routine pharmacological screening revealed that
it had analgesic and other morphine like properties in spite of its seeming
Writer
chemical dissimilarity. A Schaumann (19A0) drew attention to the phenyl
piperidine moiety in morphine and !   stressed other features which
morphine and pethidine had in common - a benzene nucleus, a quaternary 
carbon attached and a tertiary amino group two aliphatic carbons removed.
Morphine ^2^5 Pethidine
In potency pethidine was graded between codeine and morphine 
(50 to 100 mg equivalent to 10 mg morphine in man, Lasagna & Beecher 
(195*0 ) and has been found to be useful for the management of mild to 
moderate pain, especially in patients intolerant to opiates.
Originally pethidine was introduced into medical practice with 
claims of non addictiveness but it is now appreciated that'its addictive 
liability is similar to that of morphine (doses of 120 mg may substitute 
for 50 mg morphine (Eddy et al 195&)). Its toxicity is low but its actio
somewhat shorter than that.of morphine. At an equivalent dosage, pethi­
dine is at least as depressant as morphine upon respiration but while 
morphine-like side effects such as nausea and vomiting frequently occur, 
it produces little disturbance of urinary and bowel action.
In 19*tf Jensen . e\r oJ .■ ; first reported that the A acyloxy 
analogue of pethidine, the 'reversed ester1, had considerably greater
analgesic activity than the parent compound. Extensive study of this
series of phenylpiperidines by .cr (19^7) led to the synthesis
of the isomeric derivatives alphaprodine and betaprodine
potency, and betaprodine is about 3 times more active. Randall & Lehman 
(19 +^8) described the pharmacology of alpha and beta prodines and clinical 
reports on the analgesic activity of alphaprodine appeared about the same 
time (Eddy 1937)- Alphaprodine has a brief duration of action, even 
shorter than that of morphine or pethidine, and it has been used where such 
a length of effect is desirable, e.g. endoscopies, supplementation of
analgesia and obstetrics. Side effects are less than those of morphine 
and possibly less than with pethidine; its addiction liability is similar 
to that of pethidine (Eddy, 1937)-
membered heterocyclic ring, was submitted to preliminary clinical trial.
This compound, 1-methyl-4-phenyl-lf-carboxy hexamethyleneimine, was developed 
at Wyeth Laboratories in Philadelphia, U.S.A. The pharmacological 
properties of this compound were reported by Seifter et al (195^)«
OCOCLH,- 2 3
betaprodinealphaprodine
/Alphaprodine is approximately equal to morphine in analgesic
In 1933 ethoheptazine, a congener of pethidine having a seven
* Ethoheptazine Wy 401
The first clinical report appeared in 1935^** Eddy et al 1937)-
Ethoheptazine was found to have a very low addictive liability 
being less than that of codeine. It did not produce respiratory 
depression and did not seem to induce tolerance. However its potency 
was only about one third that of pethidine. In humans, this drug was 
orally effective against moderate pain in doses 50-100 mg (see Eddy et al 
1957).
On balance ethoheptazine was found to be free of most of the
I ' ' ‘ v
unwanted side effects of morphine but was a relatively weak analgesic.
It is presently marketed in combination with aspirin.
Methyl substitution in the 3 position of piperidine ring of 
pethidine had been shown to be advantageous and had led to the potent 
compounds,alpha and beta prodine. Based on this observation a more 
potent successor to ethoheptazine was found at Wyeth Laboratories in the 
form of Wy 535
CH.
hexahydro-1, 3“Himethyl -^-phenyl 
azepin carboxylic acid, ethyl ester 
Wy 535
Analgesic testing in rats and monkeys indicated that Wy 535 bad 
analgesic effectiveness greater than that of codeine or pethidine and was 
without many of the side effects of narcotic analgesics(Malis, 19621 
However clinical studies showed the compound to be convulsant in hig"h 
doses and consequently further investigation of the compound ceased.
v /  r t ?  <l /
In the late 1950’s Parke Davis & Co. had become interested in the 
pyrrolidine analogue of the prodines. . A considerable number of compounds 
in this series were prepared and details of structure activity:- relation­
ships were reported by Cavalla et al (1961). This work culminated in the 
discovery of prodilidine.
1, 2-dimethyl-3-phenyl-3- 
propionyloxypyrrolidine hydrochloride 
- prodilidine
CH.
HC1.CH.
Winder et al (1961), and Kissell and co workers (1961a, 1961b,) 
'reported their detailed pharmacological investigations on the 
compound. Its analgesic potency in rodents was generally similar to that 
of codeine when given orally but was significantly less potent than codeine 
when given parenterally. Prodilidine differed from other morphine—like 
drugs in lacking antitussive action, a constipating action, respiratory 
depression or significant cardiovascular effects except at high dosage.
Its acute toxicity was in the range of codeine. The effects of prodilidene were 
not antagonized by- nalorphine and the drug did not support morphine physical 
dependence in monkeys. While initial clinical trials looked quite promising, 
(Cass & Frederick,1963), more extensive study showed the compound to be only 
weakly active. In addition the same compound had been discovered indepen­
dently by Mead, Johnson & Co.Limited. This led to a dispute over patent 
rights and eventually neither company went ahead with it. In the meantime 
Parke, Davis & Co. had extended their investigations into analogues of 
prodilidene which eventually culminated in the discovery of profadol, 
m-(1-methyl-3-propyl-3“Pyrrolidinyl)p^en°l•
.OH
Profadol' C1 572
The pharmacological and toxicological properties of this compound 
were reported by Winder et al in 1966, when it was stated to have approx­
imately 2-5 times the analgesic potency of pethidine when given intra­
muscularly to rats. It also appeared to be a promising antitussive agent 
from studies in dogs with ammonia- induced coughs. The drug appeared to 
have both morphine-like agonist and morphine antagonist properties. Its 
antinociceptive activity in rats O'ould be antagonized by nalorphine while
it did itself precipitate withdrawal symptoms in morphinized monkeys.
Initial clinical studies were quite promising, 20-^fO mg of 
profadol given i.m. being equivalent in analgesic potency :to -10 mg morphine. 
However it seemed much less effective by the oral route only doses of p^100mg 
being significantly different from placebo,(Pearson et al 1971’).
In the course of further evaluation it was found to produce 
morphine-like subjective effects and physical dependence in human since it 
suppressed abstinence in subjects dependent on 60 mg morphine per day. 
(Jasinski et al 1971)-
Thus further development of this compound ceased once its addiction 
potential was fully realized.
In the late 1960’s studies were undertaken at Wyeth Laboratories, 
England, on homologues of profadol where the pyrrolidine ring was replaced 
by the azepine ring first seen in ethoheptazine. After investigations
into a large number of compounds in this series dl-rn(3^ethylhexahydro-1- 
methyl-1H-azepin~3-yl) phenol hydrochloride, meptazinol, was selected as 
being the most promising.
Meptazinol - Wy 22811
HC1
v _ _ / 6h3
This compound was shown to be a potent analgesic in rats, mice and 
monkeys (Goode & White, 19?f). In the hot plate test in mice meptazinol and 
profadol were shown to have similar subcutaneous potencies. ■ The EJD^ -q for 
meptazinol in this test was found to be k.O mg/kg while that for profadol 
was 3-33 mg/kg. Using the acetyl choline induced writhing test in mice, 
these compounds were again found to have similar subcutaneous potencies 
(EDj_q for meptazinol was 0.9 mg/kg and that for profadol 0.7 mg/kg).
MEPTAZINOL
N-CH,
HO' ''o' OH 
MORPHINE 
(First isolated in pure form 
in 1803)
PC0C2HS
.-CHx
CHS
ALPHAPROD!NE
,QC0C2Hs 
H
\N 
CH3  
BETAPRODINE
(1947)
IVySJS
% ° ~ c2 Hs
CHj (1962)
PETHIDINE[L3 iU’-Ji  i w> i  ii nmMtrii r in T «
2 s (1939)
PROFADOL
(1966)
ch3 ethoheptazine
(Wy 401 I9SS)
0C0C2HS
N  'C/* 
dHj j
PRODILIDENE (1962) 
OH
MEPTAZINOL
(1970)
Both profadol and meptazinol had similar i.v. LD • values in the rat; 
being approximately 35 mg/kg.
Meptazinol and both enantiomers showed opioid antagonist activity. 
Thus o.n intravenous infusion, these compounds-reversed the symptoms of 
severe morphinism in rats after a high subcutaneous dose of morphine and 
also,after subcutaneous injection, they precipitated withdrawal symptoms 
in morphine dependent rats. The (-) enantiomer was a more potent anta­
gonist than the (+) enantiomer.
0
j In a further test of dependence liability it was found that at 
doses equally analgesic to the maintenance dose of morphine, meptazinol 
and its enantiomers did not prevent the withdrawal weight loss in morphine 
dependent rats, (see Fig. 3)«
In dependence liability studies in monkeys meptazinol showed 
apparently less addiction liability than profadol, since after chronic 
administration to monkeys (^ -0 days profadol, h8 days meptazinol) and subsequent 
.withdrawal, the withdrawal signs were minimal for meptazinol (grade 0-1 on 
an 8 grade scale) whilst for profadol these signs were of mild to moderate 
severity (grade 3)- In a single dose studies in morphine dependent 
monkeys it was found that the abstinence precipitating potency of mepta­
zinol was 1/^fOth that of nalorphine, being approximately twice the potency 
of profadol (l/80th nalorphine).
Thus it would seem that one of the most potentially important
/>
advantages of meptazinol over profadol is its apparently lower addictive 
liability. Indeed the phenomenon of "Straub tail" in mice indicative of 
high addiction potential was not seen after meptazinol administration but 
was observed after profadol dosage.
Potential areas of application of metabolic studies in the development of 
meptazinol
(1) Higher addictive liability of a potential metabolite of meptazinol
In the course of addiction liability studies carried out on a
number of the.more potent analgesics in the meptazinol series, the nor-
j
compound of meptazinol, designated Wy 2280^ -, was shown to partially prevent 
the weight loss normally seen on withdrawal of- morphine from morphine 
dependent rats(See Fig* 3«) This property is common to compounds possessing an 
addiction potential. However, no such effect was seen on giving meptazinol. 
itself to dependent rats from which morphine had been withdrawn. Never­
theless the potentially higher addictive liability of norraeptazinol assumed 
considerable significance in view of the possibility of its formation by 
the metabolic N-demethylation in other species.
Indeed, N~dealkylation is a very common metabolic step in the
biotransformation of analgesics. For example N-demethylation of pethidine
14
was established by the detection of CCL, in the expired air of rats given
-1 Zi
N- CH^ labelled material, (Plotnikoff et al, 1952), and by the identifica­
tion of norpethidine in the rats’ urine. In man, the same metabolic 
pathway has been established by the isolation of norpethidine'from human 
urine (Plotnikoff et al, 1956). These workers found that total demethylated 
products in human urine accounted for approximately 30% of the administered 
dose.
Evidence that codeine is N-dealkylated was established by the
iZf -]Zj.
fact that after administration of-N- CH^ labelled codeine, CO^ appeared 
in the expired air and norcodeine was identified in the urine. Roughly 
10% of the dose was excreted as norcodeine largely in the conjugated form.* 
N-demethylation is an important metabolic pathway for the 
disposal of propoxyphene as judged by the fact that after intravenous
1 f^
injection of-N- CH^ labelled propoxyphene to ratsjapproximately 38% of the
1 b
radioactivity was eliminated as (X^ within 27 hours (Lee et al, 1959)-
Milthers (1961 and 1962) has reported the quantitative recovery by 
paper chromatography of normorphine from the urine and faeces of morphine 
treated rats. The total amount of normorphine excreted was 8-9 per cent of 
the dose given. In vitro evidence of the biotransformation of morphine to
♦(AdlerT-1955).
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' In*normorphine is also available. Under aerobic conditions CO was 
1 , 2 
released from rat liver slices incubated. with-N- CH^ morphine as
substrate,(March & Elliottj195^)•
I •
I
From metabolic studies on ethoheptazine reported by Walkenstein
et al, (1958) it was tentatively suggested that the N~demethylated product
had been identified in rat urine. Later, in studies on (hexahydro 1-3
1dimethyl-^--phenyl-azepine-^- C-carboxylic acid ethyl ester) Wy 333 1 an analogue 
of ethoheptazine* Walkenstein et■al (1965) positively demonstrated 
the presence of the nor compound in rat urine.
In view of the relatively high addictive liability of normeptazinol 
and the distinct possibility of its formation from meptazinol, investigations 
into the rate and extent of demethylation in various species formed a major 
area of metabolic interest in the early stages of the development of the 
compound. Such studies were considered to be particularly important at 
that time since addiction liability data had then only been obtained in the 
rat.
(2) Differences in intensity of biological effects of meptazinol
dependent on species and route of administration
Detailed investigations into the pharmacological and toxicological 
properties of meptazinol revealed a considerable difference in intensity of 
biolqgical effects of the drug depending on the route of administration.
For example in the rat tail flick test the dose which caused a 30$ analgesic 
response was 32 mg/kg when the drug was given orallypbut only 8.73 mg/kg 
was required to elicit the same response when the compound was administered 
subcutaneously. A similar difference between the oral and parenteral acute 
toxicities of the compound was seen viz. L D ^  (p.o.) = 1260 mg/kg whereas 
intravenously the compound produced deaths at -^0-50 mg/kg.
These route dependent differences in the biological activity of 
the compound were much more pronounced in the monkey. In the leg shock 
test in this species, the dose which produced a 30$  increase in shock
threshold when the drug was administered intramuscularly was 6.0 mg/kg.
However after oral doses up to 10 times this, ho significant increase in 
the shock threshold was observed. See Fig. f^. A similar picture emerged 
with respect to the drug's toxicity in this species i.e. considerably greater 
toxicity after parenteral compared to oral dosage. Marked toxic effects 
such as tremors and convulsions were observed at doses of 13 mg/kg intra­
venously. However these animals tolerated doses up to 1600 mg/kg (male)and. 
2300 mg/kg (female) when the drug was given orally.
Preliminary clinical studies on the drug showed that while it 
produced good analgesia after parenteral administration of doses of 20-^ -0 mg, 
very much higher doses were required'to elicit the same effects after oral 
administration. Thus only oral doses in excess of 230 mg produced significant 
analgesia in patients. In this respect the properties of the compound were 
more similar to those seen in the monkey than in the rat. While the oral/ 
parenteral ratio in the rat was only in the monkey it was least 10:1 
which was similar to man. On this basis the monkey looked to be the more 
useful model for studying the causes of the relatively low oral potency of
the drug in ,man. Clearly this v/as to form a major area of metabolic interest 
in this compound particularly in view of its relatively high synthetic cost.
Any improvement in potency which could be brought about from an understanding 
of the reasons for its low oral activity would obviously be of considerable 
commercial benefit.
Essential to an understanding of the reason for the drug's relatively 
low oral potency must be an assessment of the significance of blood and 
tissue levels of the drug in relation to its effects. If the drug per se 
is responsible for the observed biological effects of the compound and if 
it exists in rapid equilibrium, between blood and its target organ viz. the 
CNS,.it may be expected that a correlation should exist between the intensity 
of the drug's effects.and plasma levels of the compound. The demonstration 
of such a correlation would allow interpretation of any species or dosage
Analgesic activity of Meptazinol In the rat 
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route dependent differences that may be seen in plasma levels of the drug.
Correlations of this type have been established for several 
analgesic drugs including pentazocine (Berkowitz, 1971) morphine,methadone 
and codeine (Miller & Elliott, 195^)- However it is by no means mandatory 
that such a relationship should exist. For example no correlation could 
be established between propoxyphene plasma levels and intensity of analgesia 
in women suffering past-partum cramping (Wolen et al 1971) or between levels 
1 a acetyl, methadol and its pharmacological effects in rats (Sung & Way 195^)•
between blood levels and activity for interpreting species differences in 
the drug's biological activity, this was investigated in a number of species.
Possible explanations for the species and dosage route dependent differences 
in the biological effects of meptazinol
These large dosage route dependent differences in the intensity 
of the biological effects of meptazinol may have been due to one of a number 
of factors or indeed a combination of these. For example inefficient 
absorption of the drug from the gastro-intestinal tract may be a major factor. 
Alternatively variations in the extent of tissue or plasma binding of the 
drug would affect its biological availability. Differences in rates of 
metabolism and excretion would also have a profound effect on the drug's 
biological activity.. ^
(a) Absorption - A number of major analgesics including morphine and its 
surrogates have been reported to be only poorly absorbed from the gastro 
intestinal tract. For morphine this has been ascribed to its high pKa and 
the relative aqueous and lipid solubilities of the ionized and unionized 
forms. It is perhaps pertinent to set out the current concept of drug 
absorption in view of its importance to drug action. Based on this under­
standing it should be possible to speculate on how well meptazinol is likely 
to be absorbed.
Thus in view of the usefulness of demonstrating a relationship
The elucidation of the factors affecting drug absorption is 
generally attributed to Schanker & colleagues (g 1958). Absorption
is considered to take place by a process of passive diffusion, an assertion 
based upon the observation of direct proportionality between the concentration 
of drug in the gut and the amount of drug absorbed. An additional 
indication•of a simple nonsaturable process is seen in the failure of one 
drug to compete with another for transfer. ,
It appears that the absorption process involves diffusion of 
unionized lipid soluble drug molecules. Furthermore the relative lipophilicity
j
of the unionized molecules may determine their speed of passage across 
the intestinal epithelium. Evidence for this was furnished 
by Hogben et al (1959) who demonstrated a rough- parallelism between the rate 
of absorption of various weak electrolytes and the lipid to water partition 
ratios' of their unionized forms. However since drug absorption takes place 
essentially from solution the aqueous solubility of the unionized form is also 
a major determinant in this process.
Meptazinol is a weak organic base having a pKa value (for the
nitrogen atom in the azepine ring) of 8.7* Thus even under the highest
physiological pH found in the G.I. tract the compound will exist predominantly
in the ionized form. Despite this, the small proportion of unionized
molecules existing in the gut exhibit a good lipid/aqueous solubility profile.
Meptazinol free base is readily soluble in lipophilic solvents such as
/>
toluene and yet is also relatively soluble in water (200 pg/ml). This 
indicates that the compound m y  in fact be well absorbed, a suggestion 
supported by metabolic studies carried out by Walkenstein in 196^ on the 
structurally related compound Wy 535i who showed that this compound was 
rapidly and near completely absorbed after oral dosage to dogs. Similar 
results were obtained by. Chang (personal communication from P.J. Nicholls) 
with p'rofadol another compound structurally similar to meptazinol.
Thus on balance it seems likely that meptazinol may be well 
absorbed although such a prediction would necessarily have to be confirmed 
by practical study.
(b) Metabolism i
An alternative explanation for the relatively weak oral potency 
of meptazinol may be that the drug is more rapidly■metabolized to 
pharmacologically inactive products by this route of administration..
Following oral dosage the drug could be metabolized during its 
absorption through the gut-wall. For example morphine has been shown to 
be extensively conjugated,with glucuronic acid by intestinal microsomes.
(del Villar eh cj -,197^)* Although the rate of morphine glucuronidation by 
intestinal microsomes was found to be slower than in the liver it was 
suggested that metabolism in the gut wall nay be at least partly responsible 
for the reduced analgesic effects of the drug seen after its oral 
administration.
Once absorbed the drug passes to the liver where again it will be 
subject to metabolic attack, thus diminishing the amount of free drug 
that will eventually enter the general circulation and reach the brain.
From studies using C labelled morphine given to man, Brunk & Delle (197*0 
concluded that the reason for the drug's lower oral analgesic potency was 
not poor absorption but rapid inactivation in the cells of the intestinal 
mucosa and liver. This conclusion was based on the observation of good 
urinary recoveries of radioactivity irrespective of whether the drug was 
given orally or parenterally. Plasma levels of free morphine were approximately 
10 times higher after parenteral administration than when the same dose 
was given orally.
Conjugation appears to be a major metabolic pathway for the 
disposal of phenolic analgesics such as morphine and its surrogates (Way &
Adler, 1962). For example morphine 3-glucuronide was isolated from the ,urine
of addicts and shown to represent the major metabolite of the drug.
(Fujimoto & Way 195*N 0957? &. 1958). The .same was true of morphine 
metabolism in the dog (Woods, 195*N Seibert et al 195*0. Levorphanol 
has also been shown to rapidly undergo conjugation from both in vivo and 
in vitro experiments (Fisher & Long 1955)- Similarly conjugation has 
been shown to represent a major route of metabolism of pentazocine
(El-Mazati & Way, 1971).and profadol (Chang, 1968). Thus, in view bf these 
reports it seems quite probable that a major route of metabolism of
0
meptazinol will involve conjugation with glucuronic acid. -Leno 1.'. c
Although conjugation may form a major route of metabolism 
of meptazinol several other metabolic transformations are possible.
Walkenstein (1958) studied the metabolism of the structurally similar 
analgesic ethoheptazine. He reported that one of the major metabolites 
of this compound was the result of hydroxylation in the azepine ring although 
the position of substitution was not known. In later studies on the 3 methyl 
analogue of ethoheptazine, Wy 9355 Walkenstein (196£>) found no evidence for 
a hydroxy metabolite of this compound. Thus it was suggested, that the 
hydroxyl group in the ethoheptazine metabolite was probably located on either 
carbon 2 or 3 of the azepine ring, positions which are blocked directly 
or sterically by the 3 methyl group of Wy 535• By analogy with etho­
heptazine, meptazinol may also undergo hydroxylation in the azepine ring.
Such a compound, should it be formed, would probably .-subsequently undergo 
conjugation. In his concluding remarks on the metabolism of ethoheptazine, 
V/alkenstein speculated on the possibility of cleavage of the azepine ring 
at the nitrogen atom, a suggestion that could equally well apply to 
meptazinol.
Studies on the metabolism of profadol by Chang et al (1968) 
showed that this compound also underwent oxidation in the nitrogen hetero­
cycle (in this case the pyrrolidine ring) but the product was the 2 oxo
rather than the hydroxy compound. A similar biotransformation has been 
reported for the pyrrolidine ring in nicotine.•(McKennis, 196b). This
undergoes oxidation at the a carbon atom to give cotinine.
N-oxidation is a further possibility for metabolic transformation 
in the azepine ring. N oxidation of the pyrrolidine ring in nicotine has 
been reported by Booth & Boyland (1970) who also suggested this substance 
may be involved in the carcinogenisis; produced by ,nicotine.
Metabolism in the aromatic ring of meptazinol remains a possibility 
in the biotransformation of this drug although no'reports of hydroxylation 
of the similar aromatic rings of pethidine, ethoheptazine? Wy 93b or 
prodilidene have appeared.
Studies on the metabolism of glutethimide (Keberle, 1962) showed 
that a major metabolite of the drug was the result of hydroxylation in the
ethyl side chain.
CHOHCH.
oxidation,
snjdeof e: Mglutethimide H
It is a possibility that the ethyl side chain in meptazinol may 
undergo a similar fate. ■ "
On the commercial significance of metabolite identification
The commercial interests of a company developing a new drug 
dictate that it shall protect its discoveries by patent. Clearly a company 
must have the right to reap the benefit of its researches otherwise there 
would be no incentive for-expensive long term investment in research. 
Compounds covered initially by patent are likely to be those members of the 
series that have been shown to have pronounced pharmacological activity.
They may not necessarily include metabolites which may retain part or even 
be wholly responsible for, the pharmacological activity of the parent drug. 
Several examples are to be found where drug metabolites have demonstrated 
an improved profile of action compared to the parent drug, i.e. fewer unwanted 
side effects, more useful duration of action, or greater potency. Such 
compounds include oxyphenbutazone - a metabolite of the anti-inflammatory 
agent phenylbutazone and oxazepam, a metabolite of the anxiolytic, diazepam. 
These metabolites have subsequently been marketed as drugs in their own 
right. This demonstrates the need for adequate patent protection of drug 
metabolites. Of course, fundamental to patent protection of metabolites 
is their identification subsequent to biological evaluation. Thus 
elucidation of metabolite structures must form a major area of study for 
the industrial metabolic biochemist.
Summary of proposed metabolic studies on meptazinol
In applying the study of drug metabolism to the•development of 
meptazinol it was clear that emphasis should be placed in a number of 
specific areas. In view of the greater addictive liability of the nor- 
compound,Wy 2280^,studies on the extent of its formation by N-demethylation 
of meptazinol in various species, but particularly man, assumed considerable 
importance in the earlier stages of the drugs development. An understanding 
of the reasons for the low oral.potency of the drug necessitated investiga­
tions into the drug's absorption distribution and metabolism. The successful 
elucidation of the factor or factors involved could clearly have commercial 
benefit in view of the high synthetic cost of the drug. The identification 
and biological screening of the metabolites of the drug might reveal compounds 
with more useful biological properties and would enable patent protection to 
be taken out on any such compounds.
CHAPTER 2.
GENERAL 
MATERIALS AND METHODS
Materials ;
i .f .
Radiochemicals
The radiolabelling of meptazinol was carried out by Dr. Alan 
White, Medicinal Chemistry Department, Wyeth Laboratories (U.K.).
The synthetic routes involved are shown in fig. 1.
'lbN~ CH meptazinol was prepared by radioactive methylation of the 
desmethyl compound with radiocarbon labelled formaldehyde. The final 
product was shown to be radiochemically 95% pure by thin layer 
chromatography and reverse isotope dilution. Specific activities of 
various batches ^ ranged from 0.73 - 9-30^Ci/mg.
Randomly tritiated meptazinol was prepared by catalytic exchange 
with tritiated water at the Radiochemical Centre, Amersham, U.K.,
(tritium labelling service, code T.R.1) Labile tritium was removed by 
repeated dissolution in a hydroxylic solvent and subsequent evaporation 
under vacuo. The biological stability of the tritium in the molecule was 
demonstrated by the absence of significant quantities of tritiated water 
in the urine of rats and monkeys dosed with the compound. The radiochemical 
purity of the preparation was greater than 90% and the specific activity 
was approximately 70yt-tCi/mg. '
Meptazinol, specifically tritiated at the 7 position of the 
azepin ring was prepared by reduction of the corresponding ketone with 
tritiated sodium borohydride. The final product was at least 95°/° 
radiochemically pure and had a specific activity of 10 ><Ci/mg.
r *
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Animals ;1 1 II t
Rats_. Male and female COBS* rats-,- CD strain,-descended from Sprague-
Dawley were supplied by Charles River (U.K.) Limited, Manston, Kent.
' ' i
They were maintained on a diet of Oxoid VlB pellets and weighed between
200-300 g at the time of use.
Guinea Pigs. Male guinea pigs, CR-MH strain, descended from Dunkin Hartley 
were obtained from Charles River (U.K.) Limited. They v/ere kept on a diet 
of Coney brand rabbit pellets (manufactured by British Oil and Cake Mills) 
and weighed approximately 230 g at the time of use.
Hamsters. Female Syrian hamsters, approximately 130 g in weight were 
supplied by Charles River (U.K.) Limited. They were kept on Oxoids' 
'Breeding Diet1.
Mice. Male COBS* mice, CD-1 strain, were obtained from Charles River 
(U.K.) Limited and were maintained on Oxoids' 'Breeding Diet'. They 
weighed 18-22 g at the time of use.
Monkeys. Male and female Red Patas monkeys (Erythrocebus patas) weighing 
3-3 kg were supplied by Shamrock Farms Limited, Brighton, Sussex. They 
were maintained on an Oxoid A1B diet supplemented by fresh fruit.
Human subjects. Healthy male subjects 60-93.3 kg in weight and 27-33 years 
old volunteered to participate in these studies. None of the subjects had 
any recent history of prolonged drug therapy.
Dose administration, sample collection etc.
Rats.
All animals were starved overnight and for two hours following 
drug administration but were allowed access to water ad libitum. For oral 
administration the drug was given by intubation as the hydrochloride salt 
in isotonic saline. The usual dose given was 25 mg (with respect to the 
salt)/kg body weight and the vehicle volume 10 ml/kg body weight. For 
intravenous dosage the animals received the drug at 8 mg/kg in saline via 
a tail vein, the dose volume on these occasions being 1 ml/kg. In blood 
level studies following intravenous administration the compound was given 
via the external jugular vein which was exposed and cannulated while the 
animals were under halothane anaesthesia. After drug administration the 
cannula was removed and the vein ligated and the animal allowed to regain 
consciousness.
Heparinized blood samples, 100-200 pi, were collected from a tail 
vein and the plasma separated by centrifugation using a Beckman Microfuge 
(Beckman Instruments Limited, Croydon, Surrey). Urine and faeces were 
collected at intervals while the animals were housed in Jencons All Glass 
Metabolism Cages (Jencons Limited, Hemel Hempstead, Herts.).
continued overleaf
Expired CC^ was trapped by drawing air into the cages and out through 
scrubbers containing 33% ethanolamine in ethoxy ethanol.
Collection of tissue samples was carried out after killing 
the animals by ether intoxication or by cervical dislocation.
Guinea Pigs - Unstarved animals received the drug by oral intubation 
at 23 mg/kg in isotonic saline. The animals were housed in Jencons All 
Glass metabolism cages for the separate collection of urine, faeces and 
expired CC^.
Hamsters - Unstarved animals were used as described for Guinea pigs.
Mice - Starved mice were given the drug by oral intubation at 25 mg/kg 
in isotonic saline. Blood was collected by exsanguination from the 
severed jugular vein.
Monkeys - The monkeys were deprived of food for 16 hours prior to and 
for 2 hours after, giving the drug but were allowed free access to water.
For oral administration the drug was given by intubation as a solution in 
isotonic saline, 25 mg/kg in a vehicle volume of 5 ml/kg bodyweight. For 
intravenous dosage the compound was given via a femoral vein at 8 mg/kg in 
isotonic saline, the vehicle volume being 1 ml/kg bodyweight.
Heparinized blood samples 2-3 ml were taken from a femoral vein. 
Tissue samples were removed immediately after death induced by intravenous 
dosage of sodium penthothal or saturated magnesium sulphate solution. Urine 
and faecal collections were made while the animals were housed in either 
purpose built stainless steel metabolism cages (National Iron & Wire Co. 
Limited,. Manchester) or in ordinary cages (E.K. Bowman Limited, London) 
modified by the addition of a sloping urine collection tray.
Humans - Volunteers refrained 'from eating for 8 hours prior to and 2 
hours after being given theridrug. For oral administration the drug was
given in gelatin capsules containing lactose as a filler. Each capsule
-i L x
contained 50^Ci C labelled and 150yj(Ci H labelled meptazinol in a total
of 200 mg of the drug. In studies on the parenteral disposition of the
the drug the compound was given as a solution in 5% w/v dextrose. Each 
subject received 2 ml containing 20 mg.meptazinol via a cephalic vein.
The amount of radiolabelled material contained in 2 ml solution was 23^Ci 
of radiocarbon and 90^Ci of tritium.
Heparinized blood samples (10-20 ml) were taken from a cephalic 
vein at various times after dosing. Urine was voided directly into 
plastic collection bottles. Similarly stools were passed directly into 
small plastic pots.
Measurement of Radioactivity -
Radioactivity was determined by liquid scintillation counting 
in a Packard 'Tricarb' spectrometer, model 3380,equipped with automatic 
external standardization. Counting efficiency correction curves 
(external standard ratio (E.S.R.) vs efficiency) were determined by chemical 
quenching (using chloroform) of the appropriate scintillant to which had 
been added known amounts of a labelled standard (hexadecane). Comparison 
of the efficiency correction curves prepared by chemical or colour quenching 
(using Sudan Yellow in toluene) showed them to be very similar except at 
radio carbon counting efficiencies <30^.
Counting dual labelled samples
Radiocarbon activity in dual labelled samples was determined by 
using a restricted ’’window” setting which virtually eliminated any inclusion 
of tritium counts in the carbon channel. In order to determine tritium 
in dual labelled samples a correction for spillover of carbon into the 
tritium channel had to be made which involved calculation of the isotope 
ratio, i.e.
Isotope ratio = efficiency of counting tritium in tritium channel 
efficiency of counting carbon in tritium channel
Application of this ratio allows the fraction of the observed counts in the
tritium channel actually due to tritium to be determined. This ratio was 
determined at different levels of quench. Application of this ratio and 
subsequent correction for counting efficiency was made by a dedicated 
computational facility. (Packard, Automatic Activity Analyser).
Scintillants and methods of sample preparation
Scintillants used were TBS(foluene containing 8 g/litre butyl PBD 
supplied by Koch Light, Colnbrook). Instagel from Packard Instruments 
Limited, Reading, and NE260 from Nuclear Enterprises Limited, Edinburgh. 
Urine and plasma were counted directly in Instagel or NE260. In some of 
the earlier experiments urine was counted in a dioxan based scintillant 
containing 85 g napthalene and 8.3 g butyl PBD/litre dioxan while plasma was 
counted in a scintillant composed of 300g triton X100 + 8g butyl PBD/litre 
toluene.
Tissue samples and whole blood were subjected to an Tn vial' 
digestion procedure similar to that described by Mahin & Lofberg (1966).
Up to 230 mg (wet weight) of tissue or 230yxl whole blood was placed in 
suitable scintillation vial (Packard,low potassium glass vials^type 6001030),
0.3 ml 70% v/v perchloric acid and 1.0 ml 100 vol. hydrogen peroxide were 
added and the vial tightly closed, the polythene scive in the lid forming 
a gas tight seal. After heating for 1 hour at 70° the vial was cooled 
(-20° for 13 mins.) and 10 ml scintillant (NE260 or Instagel) added.
In some earlier experiments a scintillant composed of 333g triton X100 +
8.3g butyl PBD/litre toluene was used.
Initially faecal samples were extracted with methanol and the 
residue dried and digested as described above. The radioactivity in the 
extract and in the residue was then determined by liquid scintillation 
counting. However in later experiments, the faeces were pulverized using 
a Colworth Stomacher A00 (A.J. Seward & Co.Limited, London). A stiff 
sludge ca 50% w/v of faecal material in aqueous methyl hydroxybenzoate
(0.05%) was prepared in this way. 200-400 mg samples were weighed out 
and digested with perchloric acid' and'hydrogen peroxide as described 
earlier. /
Thin layer chromatography
Methanolic samples were applied to precoated silica gel plates 
(type 3713, E. Merck, Darmstadt, supplied through Anderman & Co.Limited, 
East Mosely, Surrey), which had been dried throughly before use at 100°.
Solvent systems employed included -
M- •
1. Toluene/ethanol/ammonia 79 : 20 : 1.
» *
2. Chloroform/isopropanbl/ammonia 60 : 30 : 1.
3. Ethyl acetate/acetic acid/methanol/water 60 : 13 : 13 * 10-
4. Ethyl acetate/ethanol/diethylamine/dimethylformamide 12 : 6 : 1
3. Acetone/chloroform/acetic acid/water 40 : 40 : 20 : 3»
6. Benzene/dioxan/ammonia* 90 : 43 J 4.
*ammonia was a 33^ aqueous solution of ammonia specific gravity 0.88.
Radioactive bands were located after T.L.C. either directly by 
scanning using a Panax Radiochromatogram scanner (Panax Equipment Limited, 
Mitcham, Surrey) or by apposition autoradiography in which a thin layer 
plate was maintained in contact with a sheet of X ray film (Kodak RP 34 X-< 
mat) in a light tight cassette (Kodak 8n x 10” X ray cassettes). After a 
suitable period, 1-7 days, the film was developed in Kodak DX80, fixed in 
FX40, washed and dried. Densitometer tracings of some of the autoradio­
graphs were made using a Chromoscan densitomater (Joyce-Loebel Instruments 
Limited, Newcastle upon Tyne.)
Extraction of drug and metabolites from biological fluids
Following a report by Hess et al, (1972) in which it was 
demonstrated that a number of drugs, including haloperidol, morphine and 
chloropromazine could be extracted directly from plasma using a toluene
based scintillant, it was found that meptazinol could similarly be
I
quantitatively and specifically isolated from plasma in this way.
/
Plasma 0.1 - 2.0 ml (in a scintillation vial) was basified by 
the addition of either a small quantity of ammonia solution or by the use 
of 0.03M bicarbonate buffer pH 9»5* 5 °f ’cold carrier' meptazinol was
added to reduce losses due to adsorption to glassware etc. 10 ml of TBS 
was added and after agitation for 20-30 secs, on a vortex mixer, 8 ml was 
transferred to another vial. This was shown to represent radioactivity due 
only to the unchanged drug. The residue, representing polar metabolites 
was solubilized in 13 ml Instagel or NE260 and counted.
Unchanged drug in urine was extracted in a similar fashion. In 
the case of tissue samples, 20% aqueous homogenates were prepared with the 
aid of a Silverson Mixer/Emulsifier. The homogenates were alkalinized and 
solvent extracts prepared using heptane containing 2% isoamyl alcohol.
Aliquots of the extract were taken for liquid scintillation counting.
Again this solvent extraction procedure was shown to be quantitative and 
specific for meptazinol.
The limits of sensitivity of assay of unchanged drug were calculated 
on the basis that only counts which were twice the background above background 
.were significant. The actual limits of sensitivity varied depending on the 
specific activity of the drug, the volume of biological fluid extracted and 
the proportion of the extract taken for counting.
Isolation of metabolites from urine was accomplished by the use 
of XAD2 resin columns (Erinkman Instruments Limited, supplied through Camlab, 
Cambridge). Up to 25 ml urine was applied to the column and endogenous 
salts and pigments washed through with distilled water (2 x 25 ml). Drug 
and metabolites were subsequently eluted with methanol. The methanolic 
extract was reduced to dryness by rotary evaporation, taken up in a small 
volume of solvent and subjected to T.L.C.
Conjugated drug was liberated by pre-treatment with glucuroni­
dase. Samples of the XAj>-2 extract were incubated for up to 64 h at 37° 
with a solution of mollusc glucuronidase/sulphatase 1,200-20,000 units/ml 
urine in a chloroform saturated acetate buffer pH 5-0. After treatment, 
the hydrolysate was either extracted directly with TBS and subjected to 
liquid scintillation counting or deproteinized with methanol and subjected 
to T.L.C.
Determination of analgesic response in animals
Data on the analgesic activity of meptazinol in rats, mice and 
monkeys was furnished by Mr. P. Goode, Pharmacology Department, Wyeth 
Laboratories (U.K.). Analgesic activity in the rat was determined in 
the rat tail flick test similar to that described by D*Amour & Smith (1941). 
In the mouse, analgesic activity was assessed in the acetyl choline induced 
writhing test as described by Collier et al (1964). Analgesic activity 
in the monkey was measured by the leg shock test method of Malis, (1964).
CHAPTER 3
STUDIES ON THE RATE & EXTENT OF 
N-DEMETHYLATION OF MEPTAZINOL IN VARIOUS SPECIES
Summary
In-.view of the higher addictive liability of normeptazinol 
compared to .the parent drug an investigation was made of the extent of 
metabolic N-demethylation of meptazinol in various species including
man. Measurement of N-demethylation was facilitated by a dual isotope
-11± . 
technique in which the -N-C labelled and the tntiated drug
were given together. Any loss, of radiocarbon relative to tritium was
considered to be the result of N-demethylation.
The results showed no evidence for. dealkylation in animals with
the exception of the male rat- Encouragingly there was also no evidence
for the demethylation of the compound in man. The major urinary metabolite
in all the species examined was the glucuronide conjugate of the parent
drug.
Studies on the rate & extent of N demethylation of meptazinol in various
species. •
Introduction
In view of the higher addictive liability of normeptazinol, a 
potential metabolite of the drug, an investigation of the extent of its 
formation in various species was made.
Experimental - Studies in rodents. >
The extent of N-demethylation of meptazinol was initially determined by
1A
measuring the amount of CO^ released following the administration of the
"
-N- C'Hf labelled compound.
. 3
'ih .
The efficiency of trapping CC^ m  a Jencons All Glass metabolism
cage was first determined. A 33$? solution of ethanolamine in methanol
v/as used as the trapping agent in two •’Nilox’ columns. 10 ml N HC1
(a |wo fold excess) was added through a septum in the top of the cage to
1
a beaker containing 3-0^ Moles NaH CO^ (total activity = 2^Ci). Air,
dried through silica gel and scrubbed of atmospheric CO^ by a small trap 
of soda lime, was drawn through the apparatus by a vacuum pump.
The trapping efficiency was almost 100^ if air had not previously 
been drawn through the system for any length of time. However when air 
was drav/n through for 2.h hrs prior to initiating the reaction* the trapping 
efficiency fell to 35^-
This may have been due to partial saturation of the ethanolamine 
by atmospheric CC^- Indeed when an additional soda lime trap was intro­
duced to scrub the atmospheric CC^ more efficiently this recovery rose to 
70$>. Subsequently only freshly prepared columns of ethanolamine v/ere used.
(a) Experiments in rats
1A
Three female rats received -N- CH^ meptazinol orally and were 
placed,as a group, in a metabolism cage. Urine, faeces and expired CO^ 
were collected daily for several days after dosing. Radioactivity in 
aliquots of each sample was determined by liquid scintillation counting.
-j/f 3
C and H*labelled material together. Two male and two female animals 
were dosed orally with this dual labelled material at 23 mg/kg. The 
animals were/housed individually and Urine collected at intervals up to
: . I
three or four days after dosing. Faeces were collected daily. . Any
indication of a lower recovery of radiocarbon as compared to tritium was
1 -^
considered to be the result of loss of the C label as CO^, i.e. this 
gave a measure of the extent of demethylation.
The extent of N-demethylation of meptazinol after intravenous 
dosage was also investigated. Initially, an indication of the extent to 
which this process occurred was obtained from the' completeness of recovery
1A
of radiocarbon in urine and faeces after injecting just the-N- CH^ labelled 
material into three female rats.
* *
Later a dual label study in two male and two female rats was 
carried out and the relative recovery of radiocarbon to tritium was 
determined.
(b) Experiments in other rodents.
1 Zf
Four unstarved female hamsters were dosed orally v/ith C 
meptazinol at 23 mg/kg and were placed as a group in a metabolism cage 
for the collection of expired CCL,. A similar experiment was carried 
out in three unstarved male guinea pigs.
Studies in primates
The application of the dual label technique for studying the 
extent of demethylation is particularly useful in large animals where 
collection of CO^ could present serious practical difficulties.
(a) Experiments in monkeys
As a preliminary study (at which time only the -N- CH^ labelled 
drug was available) radiocarbon labelled meptazinol was given orally to two 
male and two female monkeys and an indication of the degree of N-demethyla­
tion obtained from the completeness of recovery.of radiocarbon in the 
urine and faeces.
* randomly tritiated
* specifically tritiated
with the dual labelled material and the amount of each isotope excreted in 
the urine and faeces determined up to three days after dosing.
In; studying the extent of demethylation after intravenous dosage,
' - I ■
the shortage of tritiated material dictated that only a single label 
study with radiocarbon, could be conducted.
'lb
In the absence of facilities for collecting expired CCL,, the
only indication of the extent to which N-demethylation occurred was the
completeness of recovery of radiocarbon in the urine and faeces. Two male
'lb
and two female monkeys received the -N- CH^ labelled drug and the amount
of C labelled material excreted in the urine and faeces over the seven
days after dosing was determined. ' .
Experiments in human subjects
The metabolism of meptazinol was studied in male human volunteers.
Two subjects, J.B. and E.M., weighing 6k and 70 kg respectively ingested
* *
200 mg each of the dual labelled drug. Two further subjects L.B. and J.S.
*
weighing 70 and 72 kg were given 20 mg of the dual labelled drug intra­
venously. Urine and faeces were collected at intervals up to 7 days after 
dosing and the extent of excretion of radiocarbon and tritium determined by 
liquid scintillation counting.
Results
Studies in rodents
(a) Experiments with rats .
The results of a preliminary study in which a group of female 
 ^b
rats had received -N- CH^ labelled meptazinol orally showed a good (approx­
imately 90%) recovery of administered radioactivity (see table 1) in the 
urine and faeces with only negligible amounts appearing in the expired CO^. 
Chromatographic examination of the urine of these rats showed the major 
metabolite to be the glucuronide conjugate of the parent drug (see Fig.1).
This preliminary indication of the failure of the compound to undergo extensive 
N-demethylation was confirmed by the results of a dual label study in which a
good recovery of both tritium and radiocarbon was found (see Fig.2 and Table 2).
*■ randomly tritiated 
** specifically tritiated
recovery of radiocarbon to tritium indicating a significant sex difference
I ■
in the metabolism of the compound. Assuming the relatively poor radiocarbon 
recovery was due; to N-demethylation about 28^ of the administered dose under-
I
goes this metabolic fate in male rats.
In studying the disposition of the drug after intravenous dosage 
preliminary studies in the female rat again showed there to be no evidence 
of extensive N-demethylation. 98% of the administered radiocarbon was 
found in the urine of these animals (see table f^). Chromatographic 
examination of the urine before and after glucuronidase treatment showed 
the major metabQlite to be the conjugate of the parent drug (see fig. 3) •
The sex difference in demethylation previously observed after oral admini­
stration, was also seen after intravenous dosage. The results of a dual 
label study (see Fig. h and table 356)showed that while both isotopes were 
recovered in similar amounts in the female rat, a relatively poor recovery 
of radiocarbon to tritium was seen -in the male animals. The extent of 
demethylation appeared to be very similar to that seen after oral dosage 
viz. about 28%. The small amount (approx. 7%) of toluene soluble radio­
activity (which would include meptazinol and normeptazinol) in the urine of 
these animals indicated that both meptazinol and its metabolite normeptazinol 
were extensively conjugated prior to excretion.
(b) Experiments with other rodent species
In studies with other members of the rodent species meptazinol
did not appear to be extensively demethylated. Female hamsters exhaled
'j Zj.
only 0.66% of the dose as CC^ while male guinea pigs produced 2.9% of the 
dose as CO^*
Studies in primates
(a) Experiments with monkeys
Initial experiments in which male and female monkeys were given
“i if "l^f
-N- CH^ meptazinol resulted in a good recovery of C labelled material.
In both sexes approximately 73% of the dose was excreted in the urine in 
the five days after dosing (see table 7). Thus, in contrast to the rat, 
no sex difference in the N-demethylation of the.compound was apparent.
dase treatment showed that at least k-0% of the radioactivity was in conjugated 
form. The absence of a sex difference in N-demethylation of the drug was 
confirmed by the results of a dual label study in which both isotopes were 
recovered in similarly good amounts. s)
After intravenous dosage too, there was no indication of extensive 
N-demethylation in either sex as shown by the good recovery of radiocarbon in 
the urine and faeces (see Tables 9a and 9b). The major product of bio­
transformation was again found to be the glucuronide conjugate.
(b) Experiments in man
I The results of studies in 'human volunteers after oral dosage of the dual
I
labelled drug showed no evidence for N-demethylation since the relative recovery 
of radiocarbon was no lower than that for tritium (see Tables 10 & 11 and 
Fig. 3). In fact the recovery of tritium was somewhat lower than that for 
radiocarbon. This may have been due to tritium- exchange the resulting tritiated 
water being eliminated only slowly by comparison to the drug and its metabolites. 
Thin layer chromatography of the urine before and after ^ glucuronidase/ 
sulphatase treatment showed the major metabolite was a conjugate of the parent 
drug. Attempted hydrolysis in the presence of a specific inhibitor of jZ 
glucuronidase, glucaro-1-^ f-lactone, established that this conjugate was the 
glucuronide and not the sulphate.
After intravenous administration of the drug to a further two 
volunteers there was again no evidence for N-demethylation as shown by the 
similarly good recovery of both radioisotopes.(see if)
Discussion
Development of the methodology for studying N-demethylation
The estimation of the extent of metabolic N-demethylation of a
14
substance is often carried out by measurement of expired CO^ after
1A
administration of the -N- CH^ labelled compound. Preliminary studies 
using glass metabolism cages for small animals have illustrated some of the 
problems encountered using this method. Saturation of the trapping agent 
by atmospheric CC>2 caused by entry of unscrubbed air into the system 
remains a serious limitation of the technique.
The collection of expired CO^ from larger animals presents further 
practical difficulties. Firstly there is currently no commercially 
available large metabolism cage which incorporates an arrangement for 
the collection of exhaled gases, Woods et al (193^ -) have however, described 
the modification of an autoclave as a gas tight metabolism cage enabling 
the collection of expired CCL, from larger animals.• Cooke & Chakraborty 
(1968) have reported on the adaptation of a dog metabolism cage for the 
collection of CC^ which involved enclosing the cage completely in polythene 
sheet. Air was drav/n through by a vacuum pump and CO^ trapped in Nilox- 
type absorption towers. Jones (1972) has described the design of a suitable 
cage for collecting CO^ from monkeys but its construction involves consider­
able time and expertise. With all these cages the correct air flow through 
the system is crucial to the animals survival. A complete or even partial 
failure of the circulating pump may result in the animal's death. This 
could prove an expensive failure both in terms of the cost of the animals 
and the relatively large amount of radiolabelled compound, to say nothing 
of the suffering the animal may be caused. The collection of expired CO^ 
from man presents additional problems. Continuous collection is, of course, 
not possible. The alternative of frequent collection of gas samples is 
not only tedious but may not fully define the excretion profile.
14
Expiration of CO^ may not necessarily give a quantitative
measure of the rate and extent of demethylation. For example, McMahon el-
14
(1963) showed that following administration-N- C'H noracetylmethadol
3
to rats an unidentified C labelled compound remained in the body for a
relatively long time having an elimination half life of 13.3 days.
This was presumably the result of the one carbon fragment (formaldehyde)
released from N-demethylation entering the general metabolic pool.
This contention was supported by the results of Neely (196 -^) who studied 
1
the fate of H CKO in rats. He found that up to '\k% of the dose was 
excreted in the urine as methionine, serine and an adduct of cysteine and 
formaldehyde.
! 1
measurement of CC^ can present many difficulties and may not, therefore
! ■ i
be the most satisfactory method for determining the extent of N-demethylation. 
The development of a dual label technique for studying N-demethylation would 
appear to overcome many of these difficulties and seems particularly appropriate 
for investigating this process in larger animals.
Speculation on the reasons for the failure of meptazinol to undergo.
N-demethylation
From the present investigations it appears that among the species 
examined (which include rat, hamster, guinea pig, monkey and man) only the 
male rat showed clear evidence of demethylating the compound. The major 
metabolite of meptazinol in rats as well as man and the monkey was .the 
glucuronide conjugate of the parent drug.
Before attempting to speculate on the reasons why N-demethylation 
did not form a major route of metabolism of meptazinol it is perhaps 
pertinent to outline the present concept of the general mechanism of N- 
demethylation.
Mammalian hepatic cells possess a group of enzymes classified as 
mixed function oxidases (Mason, 1957) which modify various compounds of 
exogenous and endogenous origin not readily handled by the general nutrient 
metabolic network (Mason, North & Vanneste 1965)- These enzymes are associated 
with the endoplasmic reticulum. Isolation and consequent fragmentation yields 
vesicles known as microsomes. At present many reactions are known to be 
catalyzed by liver microsomal enzymes and require NADPH and molecular oxygen.
In 1956 Axelrod showed that this system was capable of dealkylating many of the 
major narcotics. ' .
In their early work on the in vitro demethylation of dimethyl 
aminoazobenzene, Mueller & Miller (1953) presented indirect evidence to 
support the view that demethylation proceeded through an N-hydroxymethyl 
derivative.
Thus:- R^NCH, .‘Active L (R^NCH^OH) ^R„NH + HCHO
2 j ~7T~--- 7  2 Z ---- r 2
The hydroxymethyl intermediate is now known to be formed through
the system shown diagramatically below and was first described by Omura et al(l966)
NADP Bed.’ Fp Fe+++Prot . Cyt’P. \ / 0
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Drug.
It is now well established that this hydroxymethyl intermediate 
is involved and in certain cases is stable enough to be detected. For 
example, the active intermediate of octamethylpyrophosphoramide was 
demonstrated to be N-hydroxymethyl heptamethylpyrophosphoromide (O’Brien, 
(1957),Heath et al (1955), Spencer j (19570,Spencer et al (19570). .
A particularly relevant observation was that of Keberle et al
(1965) who among the metabolites of N-methyl c<. phenyl c<. ethyl glutarimide,
AieZ-^vj I
found the glucuronide of the hydroxy intermediate. More recently 
McMahon & Sullivan (1965) Have found an analogous metabolite of the 
herbicide diphenamid. In these cases the hydroxymethyl intermediate has 
been trapped by conversion to a stable derivative, the glucuronide. The most 
direct evidence however, for the involvement of an N-hydroxy intermediate 
in N-demethylation comes from the work of Dorough & Casida (196 -^). They 
found that the unconjugated N-hydroxymethyl derivatives were relatively 
stable metabolites ofoc napthyl N methylcarbamate and o-isopropoxyphenyl 
N-methylcarbamate.
Thus there seems to be little doubt then that the hydroxymethyl 
compound is indeed an intermediate of N-dealkyla^ion. Implicit in this 
concept must be the presence of a replaceable hydrogen on the carbon 
atom enabling substitution by the hydroxyl function. Such an attack is 
usually precluded where the c<_ carbon does not possess a displaceable hydrogen 
atom.- For example, Conney et al (1965) have shown that t-butyl ethers of 
p nitrophenol and p-hydroxy acetanilide are not dealkylated by the rat.
Similarly the 3-0-t-butyl ether of morphine is not dealkylated by the rat
but the 3-0-methyl ether (codeine) is dealkylated (Kamm et al 1971)• A
further example of the lack of N-dealkylation seen with tertiary alkyl
functions is found in the N-t-butyl analogue of methoxamine which is not
♦
dealkylated in man or dog (Burns et al, 1967).
However unlike these compounds meptazinol does possess a replace­
able hydrogen atom on the N-alkyl function and therefore meets the require­
ments for the formation of the N-hydroxy intermediate involved in the N- 
dealkylation reaction.
In addition to the necessity for a replaceable hydrogen atom on 
the carbon, McMahon (1966) drew attention to the influence of lipid 
solubility of the extent of^demethylation. He showed that increasing 
lipophilicity was accompanied by an increased rate of demethylation for 
a series of six arylalkyldimethylamines. In this respect too, meptazinol 
meets the requirements necessary for a compound to undergo N-demethylation 
being readily soluble in lipophilic solvents such as toluene.
Thus despite fulfilling at least two of the requirements for N-
demethylation - the possession of a replaceable a. hydrogen atom and
exhibition of a lipophilic character - the fact remains that the compound
does not undergo demethylation in any species examined but for the male 
rat.
In 1956 Axelrod noted that substrates with free phenolic hydroxyl 
groups are demethylated more slowly than the corresponding compounds having 
either a substituted hydroxyl function or lacking a hydroxyl group altogether. 
For example morphine is demethylated by rat liver microsomes, only half as 
fast as codeine. Similarly 3-hydroxy-N-methylmorphinan is demethylated at 
only 25$> of the rate of the corresponding 3-niethoxy compounds. Thus the 
free'phenolic hydroxyl group of both morphine and 3'hydroxymorphinan apparently 
retards N-demethylation. It is interesting to note that these in vitro 
results correlate well with the established importance of N-demethylation 
as an in vivo metabolic route.For example analgesics that possess unmasked
phenolic functions sush as morphine, levorphanol and profadol undergo 
relatively little N-demethylation in vivo compared to those compounds 
either lacking phenolic hydroxyl functions such as pethidine and ethohepta- 
zine or having etherified phenolic groups such as codeine.
studies on the N-demethylation of meptazinol is the sex difference in this 
property seen in the rat. Female rats seem to totally lack the ability 
to dealkylate the compound whereas about 30# of the dose is subject to N-. 
demethylation in the male of the species.
The significance of sex differences in the metabolism of analgesics in the rat.
drugs were first noted by Axelrod (1956). The enzymic activity in the 
female rat liver was about one tenth that of the male using morphine as a 
substrate, one half with L methadone and two thirds with pethidine.
This sex difference appeared to be hormone dependent. After administration 
of estradiol to male rats for four weeks,enzyme activity was markedly 
depressed using the three narcotic drugs as substrates. Treating female 
rats with testosterone resulted in a marked increase in enzyme activity.
rat could have important implications in the search for new drugs. The
laboratory rat is probably the most widely used .species for primary 
pharmacological screening of compounds of potential therapeutic interest.
If only one sex of the species is used a false impression of the drugfe 
activity may result. In the case of meptazinol, pharmacological evaluation 
of the compound has been confined to the female rat. In view of the 
observation that N-demethylation occurs only in the male rat one might 
speculate that the compound would behave differently in this sex, particularly 
since normeptazinol has a higher addictive liability and greater analgesic 
potency than meptazinol i-tself. (L normeptazinol has been shown to be 
approximately five times more potent than L meptazinol in the rat tail 
flick test.)
Perhaps one of the most interesting observations to emerge from
Marked sex differences in the ability to demethylate narcotic
Sex differences in the metabolism of foreign compounds by the
The observation that L normeptazinol has a greater potency than 
L meptazinol lends some support to Beckettfe hypothesis on the mechanism by 
which analgesics elicit their response (see P 16 in Chapter 1)«. However 
Beckett’s contention that analgesia is produced through the formation of 
the norcompound is not upheld by the observation that meptazinol is also 
active in the female rat were no evidence for N-demethylation was found. 
Nevertheless it could be argued that demethylation did occur at the receptor 
site but to a degree undetectable by measurements made on the urine.
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Studies on the extent of N-demethylation of meptazinol in the rat 
Table 1. Excretion of radioactivity after oral administration
14of -N- CEL, labelled meptazinol to female rats.
Day after dosing % administered radioactivity
y
Urine Faeces ' co2*
1 39.2 3-39 )
)
2 13.7 2.83 ) 0.23
)
3 1.17 1.69 )
h 1.27 1.32 n.d.
5 0.29 0.22
6 0.12 1.03 n.d.
Totals 77.82 12.87 0.23
Grand Total = 90.93$ n.d. = not determined
Table 2. Excretion of radioactivity after oral administration of
3 14H/ Clabelled meptazinol to female rats
Collection
Period
(h)
Urine
Rat 1 
^C/^H*
Rat 2
14C/,3h*
Faeces 
Rat 1 Rat 2
14c/3h* "1^C/^H*
0 . - 2 5*43/5*52 15*79/15.84 )
2 = 6 27.85/28.28 20.12/19.76 ( 8.85/9.15 20.45/19.95
6 - 1 2 31.75/31.75 20.40/20.14 (
1 2 - 2 4 13.50/13.60 12.80/12.87 /
24 - 4^ 3.29/3.39 3.90/4.11 3.57/3*91 3.54/3.69
48 - 72 0.35/0.45 0.99/1.12 ' 0.32/0.81 0.50/0.88
72 - 96 0.35/0.48 0.67/0.83 0.10/0.78 0.16/0.67
Totals 82.52/83.46 74.67/74.67 12.84/14.65 24.65/25.19
Rat 1 ' Rat 2
GRAND -TOTALS ^ C  = 95*36 =.98.11 ^ 0  = 99*32 = 99*86
Table 3« Excretion of radioactivity after oral administration of
. 3 14
H/ C meptazinol at 25 mg/kg to male rats
Collection
Period
(h)
Urine
Rat 1 
1\ / ^  H*
Rat 2 
l2fC/^H*
Faeces 
Rat 1 Rat 2
1V h *  ^ V h *
0 - 2 10.80/13.81 8.60/11.23
2 - 6 18.36/24.85 22.04/28.92
15.98/20.55 21.35/28.02
6 - 12 8.69/14.20 9.20/15.78 i
12 - 24 3.35/6.42' 4.09/7.42 /
24 - 30 1.74/2.88 0.68/1.16 )
14.05/4.53 1.15/1*68
30 - 48 0.55/0.85 0.82/1.37
48.- 72 0.32/0.57 0.38/0.82 0.43/0.89 O.27/O .85
Totals 43.82/63.58 45.81/66.70 20.46/25*97 22.77/30.55
*all results shown as % administered dose
Rat 1 Rat 2
GRAND TOTALS lZfC = 64.28 \  = 89.55 = 68.58 = 97*25
Fig. 2.
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Solvent 1 before* hydrolysis Sonant 1 after hydrolysis
A A
Origin Espsctod 
tecctre?* 
Wy22811
Solventfront
Solvent 2 before*hydrotysis Solvent 2 after hydrolysis
Wy22811
glucuionidase/sulphatase treatment
A A
Solvent system 1 = Benzene/dioxan/ammonia 90:25:1 
Solvent system 2 = Chloroform/isopropanol/ammonia 60:50:1
Table 4. Excretion of radioactivity after intravenous dosage of
-N- C'E^  labelled meptazinol to female rats
Day .after dosing % administered radioactivity 
in urine >
i 1 79.82
2 16.07
3 1.86
b ■O.Vl
3 0.17
6 0.19
7 0.17
Total 98.69
Collection
Period
(h)
Urine
Eat 1 Eat 2
Faece
Eat 1 
lZfC/^H*
;s
Eat 2
1\ y 3H*
0 - 2  
2 - 6  
6 - 1 2  
12 - 24 
2k - 48 
48 - 72 
72 - 96
17.67/16.96
16.26/13.82
12.78/12.32
10.59/10.29
1.25/2.90
0 .00/0.80
0.00/0.50
6.31/6.22
17.12/16.60
31.2V29.37
7.89/7.87
1.00/2.30
0.60/0.00
0.30/0.00
y y
TOTALS 58.55/59.59 63.56/63.26 •
Table 6. Excretion of radioactivity after intravenous administration
14 3of C/ H meptazinol to male rats
Collection
Period
(h)
Urine
Eat 1k Eat 15 
I^C/^h* li+C/5H*
Faeces 
Eat 14 Eat 15
^ 0 / \ * ^C/^H*
0 - 2 2.10/2.01 3.47/3.37 ) 
)
2 - 5 7.23/8.1k 5.56/5.47 ) 
)
3 - 8 8.68/8.40 9.82/9.66 ) 7.35/9.81 1.42/3.19
8 - 1 2 12.71/14.54
j
13.01/14.66 )
12 - 2k 15.56/22.81
)
14.96/20.72 )
2k - k8 7.32/10.98 8.84/12.61 9.00/7.52 6.42/5.79
k8 - 72 0.81/1.50 0.94/1.39 1.22/5.46 1.70/12.99
7 2 - 9 6 0.31/1.33 0.14/0.51 0.28/3.35 0.23/3.29
96 - 120 0.19/0.45 0.28/0.35 0.14/2.16 0.13/2.32
TOTALS 54.91/66.76 57.02/68.76 17.99/28.30 9.90/27.58
Eat 14 Eat 15
GEAND TOTALS ^ C  = 72.9 = 95.06 ^ C  = 66.92 .= 96.34
N.B. *Figures represent % administered dose
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Studies on the extent of N demethylation of meptazinol in the monkey
Table 7« Excretion of total radioactivity by monkeys dosed orally
•'! h.
with -N- CHj meptazinol
Collection 
Period 
■ Ch)
% administered radioactivity 
Urine Faeces
Female Female Male Male Female Female Male Male
0 - 2
225
NS
226
1.49
217
0.05
218
7.48)
)
47.05)
)
225 226 217 218
2 - 4 57-54 26.22 18.74
7.15 0.92 2.29 5-79
4 - 7 7.08 1.15 NS 14.19)
)
7.15)7 - 2 4 27-76 55-14 47.19
24 - 48 5-27 5.20 5.17 1.46 1.51 2.74 NS 1.71
48 - 72 0.55 0.21 1.12 0.25 NS NS NS NS
72 - 96 0.10 0.14 O .96 O .51 0.59 0.58 •NS 5-16
96 - 126 0.50 0.07 0.90 0.22 0.19 0.77 0.75 1-77
Total 78.20 67.60 72.11 78.11 9-14 4.81 5-04 10.45
Grand totals F 225 = 87-54
F 226 = 72.41 
M 217 = 75-15 
M 218 = 88.54
NB. NS = no sample
Table 8. Excretion of radioactivity by monkeys dosed orally with
dual labelled meptazinol
Day i 
After I 
Dosing Urine
Male
1V h
% administered dose
Faeces
Female Male Female
1V h
1 87.50/85.80 74.00/69.40 1.93/2.32 0.88/1.21
2 1.09/1.62 1.77/1.83 0.88/0.96 0.60/0.61
3 - /0.57 0.19/0.18 0.36/0.34 0.73/0.93
TOTAL . 88.59/87.99 ' 73.96/71.43 3.19/3.62 2.21/2.73
GRAND TOTALS Male 1. Female 2.
1/fc = 91.78 3h = 91.61 1/fc = 78.17 = 74.18
NB. All results expressed as % administered dose
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Table 9b Faecal excretion of radioactivity by male and
female monkeys 0-6 days following 8 mg/kg i.v. 
1^ -
administration C meptazinol
Collection Period 
(days after dosing) M 219 M 220 F 227 . F 228
1i
' 1 0.97 0.33 2.50 ■0.99
2 3.27 3.07 1.52 2.69
3 1.21 0.1A 0.8A 3.27
A 0.03 0.01 0.01 0.03
. 5 0.01 0.03 0.09 0.03
6 1.9^ 0.78 1.30 2.21
TOTAL 7A 3 ^.38 6.26 9.22
All results expressed as % administered dose.
of ''C/^H meptazinol to male human volunteers
Collection Period 
(h)
Subje
J.B.
1V h
cts
E.M.
lZfC/^H
0 - 3 20.93/20.46 27.94/23.01
3 - 6 41.07/34.33 26.98/24.81
6 - 9 / 16.82/16.29 8.22/ 8.29
9 - 1 2 J 3.37/3.69
1 2 - 1 3 2.32/2.39 1.34/1.60
15 - 24. 1.03/1.30 0.90/1.11
24 - 48 0.80/1.48 0.37/ 1- 00
48 - 72 0.13/0.63 0.09/0.37
72 - 96 0.08/0.90 0.03/0.32
96 -120 0.00/0.71 O.OO/O.98
TOTALS 82.20/78.91 69.44/63.38
Table 11 Urinary excretion of radioactivity after intravenous administration 
14 3
of C/ H meptazinol to male human volunteers
Collection
Period
(h)
, UrineJj.-D. ”
1V h
J.S.
1V 3h
L.B. FaeCes J.S.
c/3h  1,,c/3h
0 - 3 20.34/20.04 16.82/15.41 \
3 - 6 16.78/17.29 17.92/15.72
/ 0.38/0.63 r0.54/0.75
6 - 0 12.13/14.94 17.18/15.47 i
9 - 16 9.26/12.12 11.25/12.13
i ‘
16 - 24 3.16/4.13 3 .07/2.90 I )
2 4 - 4 8 1.39/2.31 ■2.15/2.65 2.10/3.15 2.7O/3.72
48 - 72 0.18/0.48 . 0.14/0.31 0.44/0.60 0.18/3.50
72 - 96 0.07/0.19 0.07/0.26 0.10/0.12 0.02/0.05
TOTALS 63.31/71.50 68.60/64.85 5.02/4.50 3.44/8.02
GRAND TOTAL Subject L.B. Subject U.S.
14C = 66.33 ‘ lZfC = 72.04
\  = 76.00 5h = 72.87
N.B. All results expressed as % administered dose.
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CHAPTER k 
ISOLATION AND IDENTIFICATION OF A 
MINOR METABOLITE OF MEPTAZINOL
Summary
A-minor metabolite of meptazinol was found in the urine of 
monkeys and man ,(but not to any significant extent in rats) and 
constituted approximately 5-10/^ of the administered dose. Data from 
comparative thin layer chromatography and infra-red spectroscopy 
suggested that this metabolite was 7-oxo meptazinol. This tentative 
identification was substantiated by the loss of tritium which had 
originally been located in the 7-position of the azepine ring. 
Biological evaluation of 7-oxo meptazinol showed it to be inactive 
in tests for *CNS. activity.
Although the major metabolite of meptazinol has been shown to be 
the glucuronide conjugate, a minor metabolite'of the drug was observed in the 
urine of monkeys and man but not to any significant extent in rats. This 
metabolite appeared to be more lipophilic than meptazinol itself as evidenced 
by its behaviour on thin layer chromatography. On chemical grounds,oxidation 
at either carbon atom adjacent to the nitrogen would be expected to virtually 
abolish the basicity of the molecule and increase its lipophilicity. Certainly 
precedents for this type of biotransformation have been reported in the 
literature. In studying the metabolism of the structurally related analgesic 
profadol, Chang:, et al (1968) identified a minor metabolite of the drug (found 
in monkey but not to any significant extent in rat urine),as 4(rn-hydroxyphenyl)
1-methyl h-m propyl pyrrolid-2-one. Several further examples of this type of 
biotransformation are to be found in the literature including the oxidation of 
tremorine to oxotremorine (Cho et al-196l), prolintane to the corresponding 
pyrrolidone (Hucker 1972.) and finally nicotine to cotinine (McKennis, 1957)-
r\ ri r~
^ N - C H 2C=CCH2-N — > N-CH C=C CH -N
V-cr
tremorine ~ oxotremorine
.CH -CH C_,H,
prolintane
CH.
nicotine cotinine
drug then it would bear a close structural resemblance to CNS depressants 
such as N-methyl glutethimide and methsuximide, and might therefore be expected 
to possess some biological activity.
isolation and identification of this compound.
Materials and methods
Reference compound(s). . For comparative purposes a sample of the 7 oxo 
derivative of meptazinol was prepared by Dr. A. White of the Medicinal Chemistry 
Department. This compound 6-ethyl-6-(m-hydroxyphenyl)-1~methylhexahydro- 
azepin ~(2H)-2~one was then used as a reference compound for thin layer 
chromatography and infra-red spectroscopy.
Subject's
Urine collected from two male subjects who had received 200 mg dual 
labelled* meptazinol orally was used for the isolation of small quantities
For the isolation of larger quantities of metabolites two further 
volunteers each ingested 1.2g of unlabelled meptazinol (as 3 divided doses 
of A00 mg taken at 8 hourly intervals). Urine was collected for 2k hours 
after the first dose.
Isolation of metabolite.
. Urine taken from volunteers was subjected to XAD2 chromatography in 
order to remove endogenous pigments and salts and potential inhibitors of 
glucuronidase such as glucaric acid. After washing these through with 
water, the drug and metabolites were eluted from the column, with acidic 
methanol.
The eluate was reduced to dryness by rotary evaporation under vacuo 
and incubated with glucuronidase (Sigma type H1, 20,000 Fishman Units/ml 
urine). The incubation was performed in 0.1M acetate buffer pHA.3 at 37° 
for up to 6k hours.
^containing specifically tritiated meptazinol
In view of this possibility considerable effort was put into the
of the metabolite
_ , . „ — —  —^ —■— — - »• w**y **^7 '*A,J-iv-,rJ“t/  ^ vw o CA U1 l/CU U.J_X'fc?U 0-L^  W X X/Xl',O-LU6XI6 j*:, >
. ■ ■ v l ' ' -7 V'L'7'.;‘ .•■"•' ’• .*.7': ''?*k>,v';„-: •.., ••'. •■* :.■•;■'..■> if .-. V/iyvt'.'-’l '; V--' ''.V.'.vV.' .
' Whibh^wasirf6und V6' exclrd5iyely',<-remoVe‘^tne';mrnbr-‘m6thb’oIitd'i;S,’; "-Subsequent :
\ *•'•. •. r.
basification and further extraction with toluene removed the de-conjugatedi- : , ;3
‘V>, *.' _i I’-j
■drug. These extracts were subjected to comparative T.L.C. & isotope J' '
- - v v>. ■ / ! »■>■• ‘/. .'-ti >"'■
; ratio analysis as described later.
.Further purification of metabolite for infra-red analysis > ■*,
The extract containing the minor metabolite was reduced to dryness s
*-W- ’ .'Ml'-y
' and^ after resolution in a small volume of solvent, (toluene/methanol 1:1)S u 
subjected to thin layer chromatography in either chloroform/ammonia/isopropanolj 
A ;60:1:30 or toluene/ethanol/ammonia 79 2^0:1. The extracts were chromatographed!
V i . : -y^ .b-vq*V
*' .on &. number of thin layer, rather than preparative layer plates since the , 5
■’ . ' 4^33^'
latter type can suffer from poor resolution. The location of the minor n  ^ )
metabolite was established by either use of a radiochromatogram scanner or .by. 
autoradiography as described in Chapter 2. The appropriate areas were scraped:-- 
/ offhand eluted with aqueous methanol. After reduction to* dryness the material5') 
. was* submitted to further thin layer chromatography in ethyl acetate/methanql/ j- 
acetic acid 8 :1:1 and' finally eluted with toluene/methanol 1:1 • '
$'*'* tCv!'V -
' ‘ • • v
Experimental ,
(1 )v Comparative thin layer chromatography h -
. • • t Samples of the minor metabolite isolated from the urine of subjects-^-:
■who(had ingested the radiolabelled drug were compared on thin layer chroma- I \ 
tography with 6-ethyl-6-(3-hydroxphenyl)-1-methyl hexahydroazepin-(2H)-2-one 
(Wy 24694) in - .
. (a) Ethanol/chloroform/heptane/water (20:10:10:3)
(b) Chloroform/isopropanol/ammonia (60:30:1) A;-■
i (c) Chloroform/acetone/acetic acid/water (60:20:20:3) :
ii The metabolite and the reference compound were also co-spotted in
■ ,ord£r to avoid any apparent differences in the chromatographic behaviour ofv- ,:--v. V
: the^materials being merely due to variations in layer thickness, edge effects,
drag effects etc. The location of the authentic Wy 24694 was established f -
.}, ‘v t  \
• : i ’ * .
' by .Tight absorption under "a ”234 nm lamp. . . •* ~ ’ *
Sufficient quantities of the minor metabolite were isolated (from the
two volunteers who had ingested 1.2g of the drug) to enable its infra-red
spectrum to be determined. . The i.r. spectrum of the metabolite and of
authentic Wy 2469^ were determined in bromoform solution using a Perkin Elmer
521 diffraction grating infra-red spectrophotometer.
3 1^ -
(3) Determination of the H/ C isotope ratio in the metabolite
If this minor metabolite of meptazinol arbs£: from oxidation at the 7 
position in the azepine ring then the tritium originally located at that 
position would be displaced. Thus after /3 glucuronidase treatment of the 
urine and subsequent T.L.C. of the toluene extracts, the tritium to radio­
carbon ratio in the bands corresponding to the minor metabolite and to the 
parent‘drug were determined.
Results and Discussion
Comparative thin layer chromatography - Chromatography in an acidic, in a 
neutral and in a basic solvent system showed the minor metabolite to correspond 
closely to the authentic Wy 2^ -69^ -, ^ see Fig.l). Further T.L.C. in which both 
materials were spotted together showed no separation indicating that the minor 
metabolite v/as probably identical with Wy 2^ 69 -^.
Infra-red analysis - Comparison of the infra-red spectra of the metabolite 
with that of V/y 2^-69^ showed them to be very similar (see Fig.2). The 
marked peak at 1625 wavenumbers seen in both spectra is probably due to the 
presence of an oxo group since it is known that, carbonyl functions absorb in 
the I6OO-I7.5O region. The small peak at 3590 may be due to the hydroxyl 
function of the metabolite. The peak at 780 indicates the presence of an aromatic 
system although this is rather small* The dissimilarity in the magnitude 
of the peak at 2920 - due to C-H stretching-may only be due to contamination 
of the biological sample with other C-H containing material.
total loss of tritium (see table 1). The initial ratio of 3:1 in the drug 
administered had fallen to ,0.2:1 in the metabolite indicating that reaction 
had occurred at the 7 position in the azepine ring.
3 1bA1though the initial ratio of H/ C had been 3 ;1 in the administered 
drug, deconjugated meptazinol recovered from the urine appeared to have a 
somewhat lower ratio of 2.3-2.^f:1. This discrepancy was probably due to 
incomplete desorption of the drug from the silica gel. (the isotope ratio 
had been determined by scraping the appropriate area of the T.L.C. plate . 
directly into a scintillation vial and adding 1 ml water' (to deactivate the 
silica gel) and 13 ml NE260. Incomplete desorption of the drug would lead 
to errors in estimating the tritium counting efficiency, an effect which would- 
be less marked for radiocarbon.
Thus the T.L.C., I.R., and isotope ratio data provides substantial . 
evidence to identify this metabolite as 6-ethyl-6-(m-hydroxyphenyl)~1- 
methylhexahydro azepin — (2H)-2-one. The overall pattern of metabolism of
meptazinol■in man is shown below -
C00H
OH
OH
major route 
of metabolism^
' \ ^ C H
MEPTAZINOL C00H
$\ ^ OH,0H OH
OH
CH_.
Q0
nave concerned tne conversion of nicotine to cotinine and it is possible that
I
a similar mechanism may also be involved in the formation of 7 oxo meptazinol. 
The mechanism of formation of cotinine was originally proposed by 
McKennis (1957) and was thought to occur via the cyclization of^ -(pyridyl)- 
-methyl aminobutyric acid. Undoubtedly this does occur on urine storage 
but Hucker et al (i960) put forward an alternative mechanism to account for 
in vitro formation of cotinine in which the primary reaction is the 
metabolic formation of 5* hydroxynicotine. This metabolite is then further 
oxidized by the soluble enzyme, aldehyde oxidase, to produce cotinine.
Recently in studying the mechanism' of formation of cotinine Murphy 
(1973) has demonstrated the presence of the Zh1 5(5‘) iminium ion in an in vitro 
reaction system. This he was able to do by chemically trapping the ion as 
the cyanide (the presence of CN would also inhibit the conversion of 5* 
hydroxynicotine to cotinine). Murphy suggested that the iminium ion is 
produced chemically from 5 1 hydroxynicotine with which it exists in a state 
of equilibrium. However if the iminium ion was so formed, after the formation 
of 5 1 hydroxynicotine, it is difficult to see its function in the formation 
of cotinine. The suggestion that the iminium ion arises chemically from 5 * 
hydroxynicotine may have been put forward since no enzyme capable of 
abstracting a proton directly from nicotine to give the iminium ion v/as known. 
However it is possible that this reaction would be catalyzed by cyt PA-50.
1
'N
3
5 1 hydroxynicotine
OH
nicotine■
nicotine
iminium ion
COOH
‘NH
CH.
cotinine
-(3~pyridyl)-^-methylamino butyric acid
CN
h
cyanonicotine
Gorrod & Jenner,(1975) drew attention to the pharmacological and toxicological 
implications of the formation of this highly chemically reactive iminium ion, 
comments which may equally apply should a similar intermediate be involved 
in the formation of 7-oxo-meptazinol.
Biological activity of 7-oxo-meptazinol
Faigle (1962) pointed out that a common feature of the chemical structure 
of many central sedative hypnotic drugs was a nitrogen containing heterocycle 
with an oxo function adjacent to the nitrogen atom. Thus the 2-oxo~piperidines, 
(Belford & Bonnycastle, 1950)? the 2-oxo-pyrrolidines (Marshall, 1958) and 
the 3-oxo-acetidines (Maffi, 1959) have all been shown to possess central 
activity. On this basis it was thought quite probable that the 7-oxo 
metabolite of meptazinol might possess some interesting biological activity.
the parent drug, 7-oxo-meptazinol appeared from its chromatographic 
characteristics to be less water soluble than meptazinol and might therefore 
be retained longer in the body and be better able to cross biological 
membranes than more water soluble metabolites.
* Consequently authentic samples of 7-oxo-meptazinol were subjected to 
pharmacological evaluation in a general screen for CNS activity in mice but 
no effects were apparent even after the highest dose (A00 mg/kg p.o.). It 
was considerably less toxic than meptazinol since at this dose, meptazinol 
was lethal to mice. In this respect it is interesting to note that cotinine 
has only l/20th of the acute toxicity of nicotine (Truhaut et al 196A).
An assessment of the anticonvulsant activity of 7-oxo-meptazinol was made in 
view of its structural similarity to methsuximide and N-methyl-glutethimide 
which are established anti-epileptic agents.
However it was found to afford no protection against metrazol or 
electroshock induced convulsions in mice. In the rat tail flick test for
J
analgesia it was also found to be inactive up to 25 mg/kg p.o. Interestingly
There remains the possibility, however, that 7-oxo-meptazinol and 
possibly 2-oxo-profadol were not well absorbed after oral administration and 
further pharmacological testing after parenteral dosage may be desirable.
•N- methyl- glutethimide methsuximide
7-oxo-meptazinol
2-oxo-profadol given p.o. at 125 mg/kg (25^ L.D.^Q) was also inactive as an 
analgesic as shown in the tail pinch test (Nicholls, personal communication).
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CHAPTER ^
INVESTIGATION OF THE RELATIONSHIP BETWEEN THE BIOLOGICAL 
ACTIVITY OF MEPTAZINOL AND PLASMA AND TISSUE CONCENTRATIONS 
OF THE DRUG.
The relationship between the intensity of the biological effects 
of meptazinol and blood/tissue concentrations of the compound has been 
investigated in rats, mice, monkeys and man. The greater potency of the 
intravenous compared with the oral formulation of the drug was reflected 
by higher plasma and tissue concentrations of the compound per unit dose. 
Furthermore the species difference in oral potency of the drug, in which 
the compound was more potent in rats and mice than in monkeys or man could 
also be explained in terms of differences in plasma concentrations of the 
drug. The greater oral potency of the drug in the rat compared to the 
monkey was associated with higher plasma concentrations of the compound per 
unit dose. A good correlation between the drug's analgesic activity and 
its plasma concentration was demonstrated in rats and mice.
In view of the greater potency of the parenterally administered
l
compound over1 the oral formulation and knowing there to exist a species 
variation in this parenteral/oral ratio, it was of interest to examine the 
plasma and tissue concentrations of the drug achieved by different dosage 
routes in these species.
Experimental
(l) Studies in rodents. (a) Eats - Three female rats were dosed intra- 
venously with C meptazinol at 8 mg/kg. Blood samples were collected 
at various times after dosing, the plasma separated and unchanged meptazinol 
estimated following solvent extraction. Radioactivity remaining in the 
residue, which would represent polar metabolites, was then determined.
For comparative purposes a further seven rats were dosed orally at 25 mg/kg 
and again plasma concentrations of unchanged drug were determined at various 
times after dosing. In addition^ the residual radioactivity due to 
metabolites of the drug was estimated.
In order to establish whether there existed a correlation between 
the intensity of the drug's pharmacological effects and plasma concentrations 
of the compound a further group of rats was dosed intravenously at 8 mg/kg 
and another, orally at 25 mg/kg and analgesic activity estimated in the 
2’at tail flick test at various times after dosing. Subsequently a plot 
was made between the observed analgesic activity and log^Q plasma concentra­
tions (generated from the line of best fit through the observed data points) 
at the corresponding times after dosing. (The line of best fit was 
determined by regression analysis using an Olivetti 101 calculator).
In order to make a comparative study of the extent of tissue localiz 
ation of meptazinol following oral or intravenous administration four female 
rats were dosed orally at 25 mg/kg and a further three rats intravenously 
at 8 mg/kg. Fifteen minutes after dosing the animals were killed and the 
major organs - liver, kidneys, spleen, lungs, heart and brain - were removed.
I  V X X U W l i l g ,  u n w  w x  u.\^u w m u  u v m w g u u u  w  x  u n w u u  uixv>
unchanged drug was isolated by solvent extraction (as described in Chapter 
2) and estimated by liquid scintillation counting.
In a study designed to compare plasma and brain concentrations of 
meptazinol at death, achieved by the oral or parenteral route of administration, 
six female rats were dosed intravenously at A-0-50 mg/kg and a further seven 
animals orally at 500 mg/kg. Immediately after death the animals were 
exsanguinated via the jugular vein and the brains removed. Unchanged drug 
was estimated by liquid scintillation counting following solvent extraction.
(b) Mice - To establish whether thet-e existed a correlation between the drug’s
pharmacological effects and plasma concentrations of the compound, the
\
analgesic activity of the compound was measured using the acetyl choline 
writhing test in groups of eight male mice at various times after they had 
been dosed orally at 25 mg/kg. Further groups of five mice were exsanguinated 
at various times after receiving the labelled drug at a similar dosage, and 
the blood from animals in each group pooled. Unchanged drug, as well as 
residual activity due to metabolites, was determined by liquid scintillation 
counting.
Studies in primates
(a) Monkeys - With the object of comparing plasma concentrations of the drug 
achieved after oral or intravenous administration, one male and three female 
monkeys were given the radiolabelled drug orally at 25 mg/kg while a further
•s,
two male and two female animals received the drug intravenously at 8 mg/kg. 
Blood samples were taken at various times up to 2^ f hours after dosing.
The plasma was separated and unchanged drug estimated after solvent extraction.
To compare the tissue concentrations of the drug achieved by each route 
of administration one male and one female monkey were given meptazinol intra­
venously at 8 mg/kg while another male and another female monkey each 
received the drug orally at 25 mg/kg. At 1 hour after intravenous and 2 hours 
after oral dosage the animals were killed and the major organs, i.e.
' V .  *>
organs were subsequently prepared and unchanged drug isolated by solvent 
extraction.
(b) Humans - Attempts were made to estimate the plasma concentration of
3unchanged meptazinol in two male volunteers who had taken 200 mg 0/ H 
labelled meptazinol. Solvent extracts were prepared from k ml samples 
of plasma obtained from blood collected'at various times after dosing.
Another two subjects were given 20 mg of the drug intravenously 
and again blood was taken at various times up to 2k hours after dosing. 
Unchanged meptazinol was estimated by liquid scintillation counting following 
solvent extraction of k ml samples of the separated plasma.
Results
(1) Studies in rodents
(a) Rats - The highest plasma concentration of parent drug after intravenous 
dosage was, not surprisingly, observed at the first point of measurement,
0.23 Hr after drug administration. The concentrations found in all three 
rats at the time were fairly consistent 1.^ -6, 0.90, 1.36}ig/ml. After oral 
administration the observed peak plasma concentration of the drug occurred 
at 0.66 h after dosing but there was considerable inter-animal variation,
0.23 - 0.86 jig/ml, with respect to the actual peak concentration achieved. 
Nevertheless the plasma concentrations achieved were clearly lower than 
after intravenous dosage of 8 mg/kg (see table 1).
- A good correlation was found between the intensity of analgesic activity 
(as indicated in the rat tail flick test) and the l°g^Q plasma concentration 
of the drug (see xables 2 and 3? figs. 1 and 2). The correlation co­
efficient after oral administration was found to be 0.80 while the value 
found after i.v. dosage was somewhat better at O.89.
Tissue distribution studies showed that the drug became localized 
in all the organs examined. Concentrations of the drug in these tissues 
considerably exceeded that seen in plasma at the same time. Tissue 
concentrations found at 0.23 hr after intravenous dosage were generally 
higher than those seen at a similar time after oral dosage of 23 mg/kg.
(see table f^).
Brain concentrations achieved after lethal doses by either route of 
administration were of the same order e.g. 131.7 +; 19*9 pg/gm was found
in the brains of i.v. dosed animals at death while the brain concentrations 
in animals that had died after oral administration was 210._+ 1A.1 pg/gm.
(b) Mice. - A good correlation was found between the intensity of analgesic 
activity as indicated in the acetyl choline induced writhing test and Io&jq 
plasma concentration of meptazinol. The correlation co-efficient was 
O .96 (see table 5> fig.3).
(2) Studies in primates
(a) Monkeys - The maximum plasma concentration seen after i.v. administration 
occurred at the first point of measurement. Plasma levels of 2.^8, 1.70, 1.^5 
and 1.A6 in the two male and two female animals contrast sharply with
the very low levels seen after oral dosage. Here the observed peak levels 
were seen at 2 -3*5 hours after dosing and did not exceed 0.11 ^ig/ml (see 
table-6).
In studies on the tissue distribution of the compound localization 
was again observed in all the organs examined. Concentrations achieved 
after intravenous dosage at 8 mg/kg were very considerably higher than 
after 25 mg/kg given orally (see table 7)«
• The oral/parenteral difference in plasma and tissue concentrations 
of the drug was very much larger in the monkey ^than in the rat.
(b) Humans - Following oral administration of 200 mg of meptazinol to male 
human volunteers plasma concentrations of unchanged drug remained below 
the limit of detection of 20ng/ml. By contrast 20 mg given intravenously 
to a further two male volunteers resulted in peak plasma concentrations
of approx. 60 ng/ml. (see table 8).
Discussion
Plasma and tissue concentrations of meptazinol in relation to dosage route 
dependent differences in the biological effects of the drug.
Meptazinol given parenterally is considerably more potent than after 
oral administration. For example the L.D.^q value in rats after giving the
drug intravenouslyvas approx. *f0-50 mg/kg whereas after oral administration 
death occurred only at doses above 750 mg/kg (unstarved animals). In the 
monkey marked toxic effects such as tremors, ataxia etc. were seen after 
30 mg/kg i.v. but orally these animals tolerated doses up to 1000 mg/kg. 
Recent studies in man showed that nausea, transient mild hypotension and 
dizziness occurred in a small proportion of subjects who received the drug 
at 50-75 mg i.v. whereas no such effects were seen after oral administration
at doses up to 200 mg. The analgesic actions of meptazinol were also more
pronounced after parenteral dosage. For example the E.D.^Q value in the 
rat after i.v. administration was 8.7 mg/kg compared to 32 mg/kg after oral 
dosage. In the monkey the E.D.,_q value after intramuscular administration 
was 6.0 mg/kg but after oral administration no analgesic effect was seen 
at doses up to 80 mg/kg. In man analgesia was readily demonstrated at
doses of 20 mg given i.v. but after oral dosage only amounts in excess of
250 mg resulted in a significant analgesic effect.
The results of the present pharmacokinetic investigation have shown 
that on a dose for dose basis, intravenous administration of the drug to 
rats, monkeys and man results in considerably higher tissue and plasma 
concentrations than after oral dosage. For example the maximum observed 
plasma level of meptazinol after i.v. administration to rats at 8 mg/kg 
was approx. 1.25 ^g/ml compared to 0.7 Jig/ml after the much higher oral 
dose of 25 mg/kg. In the monkey, plasma levels 0.25 hr. after i.v. dosage 
at 8 mg/kg were approx. 1.7 pg/ml compared to observed peak levels of only 
0.1 jig/ml after oral dosage at 25 mg/kg. In man plasma levels 0.25 hr. 
after i.v. administration of 20 mg were about 60 ng/ml compared to levels 
of less than 20 ng/ml after oral administration of 200 mg.
Quantitative comparison of tissue levels achieved by different routes 
of administration is more difficult since the time at which maximum concen­
trations occur cannot be known with certainty. Reliance has then to be
maximum tissue levels particularly in larger animals. By 0.25 hr. after 
intravenous administration of the drug to rats'(by which time peak plasma 
levels were known to be achieved) the brain concentration was approx.
15 Jig/gm (dose 8 mg/kg) compared to 2.8 jig/gni seen at the "same time after 
oral dosage at 25 mg/kg. (peak plasma levels were usually achieved by 
0.33 - 0.66 h. after p.o.dosing). In the monkey, tissue levels were again 
estimated at the time of an observed maximum plasma concentration. After 
intravenous dosage, this probably occurred within a few moments of dosing. 
However the first observed peak was not seen until 1 h. afterwards.
This may have been a secondary peak due to the enterohepatic circulation 
of the drug.(relatively high concentrations of radioactivity were found in 
the bile of animals used in tissue distribution studies suggesting the 
possibility of enterohepatic circulation.) A comparison of the brain 
levels at this time with that seen 2 h. after oral dosage, showed that 
considerably higher levels were achieved by the intravenous route^ 5 pg/gm 
(after 8 mg/kg) cf. 0.3 pg/gm (after 25mg/kg.p.o.)
That the explanation for the greater potency of the parenterally 
administered compound resides in the higher tissue levels achieved is 
further supported by a study made of the lethal brain concentrations seen 
after oral or i.v. administration. After a lethal intravenous dose of 
the compound^AO-50 mg/kg the brain level of meptazinol was 131 * ^9 
pg/gm. This was of the same order to that seen after a lethal oral dose 
when the concentration was 210 +_ 1^ f pg/gm. Thus despite a ten fold 
difference in dose leve!}., brain concentrations of the drug were quite 
similar.
Considering all the data so far gathered and in the absence of any 
evidence to suggest a different pattern of metabolism after i.v. dosage, 
it would appear that the explanation for the greater parenteral potency of 
meptazinol is that on a dose for dose basis higher blood and tissue concen­
trations of the drug are produced by this route of administration.
Plasma and tissue concentrations of meptazinol in relation to the species 
difference observed in its biological effects
In addition to the marked administration route difference in the 
potency, of drug there also exists a considerable species difference in the 
biological activity of the compound. For example analgesia is readily 
demonstrable after 25 mg/kg p.o. to rats or mice but no analgesic effect 
could be shown in monkeys given oral doses up to three times this dose. 
Furthermore rats receiving oral doses in excess of 500 mg/kg died whereas 
monkeys tolerated up to 3-5 times this dose. In man the biological 
activity of the drug resembled the monkey more than the rat. (See page 33? 
Chapter 1).
The results of the present investigations have shown that this species 
difference, like the dosage route difference in potency, can be explained 
in terms of the plasma and tissue concentration of the drug. For example 
after oral administration to rats and mice peak plasma concentrations of 
the drug were between 0.75 and 1.5 pg/ml. However after a similar dose 
to monkeys peak plasma concentrations did not exceed 100 ng/ml. Furthermore 
brain concentrations of meptazinol in rats at the time of peak plasma 
concentrations were approx. 3 pig/gm compared to 0.3 pg/gm seen in the monkey. 
Demonstration of a correlation between intensity of analgesia and plasma 
concentrations of the compound
Despite the use of two separate groups of rats,, one for estimating 
plasma levels, the other for determining analgesic effect, a.reasonably good 
correlation has been established between intensity of analgesia and the 
magnitude of the plasma concentration achieved after oral dosage. A plot 
of log-jQ plasma concentration vs. analgesic activity in the rat tail flick test 
a correlation coefficient of 0.8. Marked inter-animal variation was seen 
with respect to plasma levels of the compound particularly during the period 
immediately after dosing. This may be a result of the rapid absorption of 
the compound (see Chapter 5) since under such conditions small differences 
in absorption rate between individual animals would result in large differences 
in plasma levels observed at any particular point within the absorptive phase,
even rnougn in iact pean levels 01 m e  compuuriu. m  u m e r e n t  animais may
ii
be very similar. Furthermore, a better correlation between intensity of 
analgesia and plasma levels of the drug might -have been obtained if the 
pharmacological activity and plasma levels could have been determined 
simultaneously in each animal. However this is made difficult by the fact 
that the tail of the animal is used for measuring analgesia (tail flick 
test) and also provides the most convenient means of collecting blood 
samples, this latter process inevitably involving injury to the tail which 
would interfere with subsequent estimations of analgesia.
A somewhat better correlation between analgesia and plasma levels of 
the compound was obtained after intravenous dosage although once again two 
separate groups of animals were used. A plot of log^Q plasma concentration 
vs. intensity of analgesia gave a correlation coefficient of 0.9- This 
better correlation may be the result of avoiding the absorptive phase 
where so much inter-animal variation occurred after oral dosage.
The best correlation so far obtained was seen after oral administration 
of the drug to mice. A plot of log^ plasma concentration vs. analgesia 
gave a correlation coefficient of O.98.
Although a good correlation between intensity of analgesia and plasma 
levels of the drug has been established, a not unacceptable correlation is 
obtained if the plasma concentration of residual metabolite(s) (presumed to 
be the glucuronide) is plotted against analgesia.
Hov/ever studies in the monkey have shown that despite considerable 
circulating levels of the glucuronide no demonstrable analgesia can be seen 
after oral dosage of the drug which suggests the glucuronide is pharmacolo­
gically inactive. On theoretical grounds too, it seems unlikely that the 
glucuronide of meptazinol should possess any pharmacological activity. The 
effect of conjugation of a compound with glucuronic acid is usually to 
produce a strongly acidic derivative which is likely to be completely ionized
J /i lJ  o  J.V/CT.-L JL Kj JL O CL-LJ-J CJJ UCU. u u a u  l/Ilt?  -LXJJ-LU. o U l U U J . i l  U j
of a compound is an important factor in determining its biological activity, 
particularly for an analgesic agent such as meptazinol which has to cross 
the blood brain barrier. This appears to be related to the fact that lipid 
soluble compounds can relatively easily traverse lipoprotein biological 
membranes and thus gain access to their sites of action whereas ions which 
are poorly lipid soluble can penetrate cells only with difficulty. Glu- 
curonides, in addition to being ionized at physiological pH also tend to 
exist as bulky hydrates which would further impede their transfer across 
lipoprotein membranes. On these grounds it seems probable that glucuronide 
would be pharmacologically inactive. Indeed Woods (195^) found that the 3- 
glucuronide of morphine, isolated from dog urine, had no pharmacological 
activity when injected into mice and dogs and its administration had no 
influence on the severity of withdrawal symptoms in monkeys dependent upon 
morphine.
25 mg/kg or intravenous dosage at 8 mg/kg to female rats
ifime
After
Dosing
(h)
Intravenous
Dosage
Oral Dosage
0.16 1.46 0.90 1.36
0.33 0.90 0.30 0.20 0.36 0.15 0.65 0.75 0.59
0.42 0.71
0.50 O.63
O.67 0.74 0.57 0.23 0.55 0.66 0.76 0.80 0.48
0.75 0.64 ;
1.00 0.44 0.53 0.20 0.44 0.51 0.86 0.76 0.46
1.33 0.42
1.50 0.44 0.42 0.20 0.36 0.48 0.72 0.64 0.43
2.00 0.34 0.17 0.31 0.38 0.61 0.54 0.32 '
2.50 0.24 0.26
3.00 0.15 0.29 0.13 0.25 0.21 0.46 0.29 0.19
A .00 <0.08 0.13
4.50 0.07
5.00 0.22 0.13 0.18 0.10 0.30 0.24 0.14
6.00 £0.04 (0.08
6.50 <o.o4
7.00 0.18 0.13 0.14 0.09 0.24 0.16 0.14
9.00 (o.o4
10.00 <0.04
10.50 <0.04
10.75 0.15 0.10 0.13 0.11 0.17 0.16 0.16
12.50 <D.o4
21.00 <0.03
22.50 <p. 04
23.00 £>.04
24.00 0.06 0.07 0.07 0.05 0.11 0.10 0.11
All results expressed as ug meptazinol HCl/ml plasma.
Table 2
Analgesic activity (as determined by the rat tail flick test) and plasma 
concentrations of meptazinol (and also its metabolites) found at various 
times after oral administration of the drug to female rats at 23 mg/kg
Time after 
dosing 
(h)
Analgesic activity . 
(mean increase in 
response time, 
secs.)
Plasma Concn. of 
meptazinol 
fyig/ml) + S.E.M.
I Plasma Concn. of 
|metabolites 
j (jig eq./ml) + 
S.E.M.
0.33 3-12 0.443 + 0.098 4.32 ±  0.38
0.66 2.98 0.617 + 0.084 6.93 + 0.43
1.00 2.33 O.389 + 0.090 6.08 + 0.28
2.00 0.43 0.377 + 0.036 4.31 + 0.19
4.00 0.06 0.178 + 0.022 2.60 +_ 0.13 '
6.oo 0.66 •0.164 h- 0.020 2.40 + 0.09
8.oo 0.64 0.148 + 0.017 2.34 + 0.09 |
!
N.B. Analgesia was determined in a group of eight rats while plasma 
levels were estimated in a further group of seven animals.
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Table 3>
Analgesic activity (as determined by the rat tail flick test) and plasma 
concentrations of meptazinol' (and its metabolites) found at various
times after intravenous dosage of the drug at 8 mg/kg to female rats
Time after 
Dosing 
(h)
| Analgesic Activity 
(mean increase in 
I response time, secs.)
Mean Plasma
Conc.meptazinol
(ug/ml)
'+ S.E.M.
Mean Plasma 
Conc.metabolites 
(ug eq./ml.) I 
+ S.E.M.
0.16 3.09 1.2A + 0.17 1. 3 1 + 0.35 j
0.33 3.98 O.83 + 0.02 1.73 + 0.15 |
0.30 A .63 0.72 ±  0.06 1.96 + 0.12 |
0.67 A .89 O.63 + 0.06 2.09 + 0.21 I
0.8A 3.83 O.38 + 0.03 2.01 + 0.18 .
1.00 1.87 0.32 + 0.0A 1. 9A + 0.15
1.16 2.07 0.A7 + 0.03 1.80 + 0.1A
1.33 O.83 0.A2 + 0.03 1.69 + 0.15
1.30 0.00 0.39 + 0.03 1.58 + 0.15
N.B. Analgesia was determined in a group of eight rats while plasma 
levels were estimated in a further group of three animals.
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Table 5
Analgesic activity (as determined in the acetyl choline induced writhing 
test) and plasma concentrations of meptazinol and also its metabolites 
found at various times after oral administration of the compounds to male 
mice at 25 mg/kg
Time after 
dosing 
(h)
Analgesic activity 
expressed % inhibi­
tion of writhing
Plasma Concn. 
of meptazinol 
(pg/ml)
Plasma Concn. 
of metabolites 
(pg.eq./ml)
0.33 100 1.46 ' 7.4
0.67 100 0.74 11.7
1.00 85 0.35 7.3
1.16 73 0.29 6.4
1.33 . 48 0.24 5.6
1.50 40 0.19 4.9
1.67 22 0.14 4.1
1.84 20 0.09 3.4
2.00 0 0.06 2.7
4.00 11 40.03 .1.1
6.00 0 <0.03 0.3
N.B. Analgesia was determined in groups of 10 male mice at each time point. 
For measurement of plasma levels further groups of five mice were 
exsanguinated at various times after dosing.
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Table 6
Plasma concentrations of unchanged meptazinol following oral dosage 
at 25 mg/kg or intravenous dosage at 8 mg/kg to monkeys.
Time after 
dosing 
(h)
Intravenous Dosage Oral Dosage
M 219 M 220 F 22 7 F 228 M .220 F 228 F 237 F 289
0.25 2.48 1.70 1.45 1.46 - - 1 - -
0.33 - - - - 0.03 <o.o4 -
0.50 1.62 1.59 2.58 1.43 - - <0.01 < 0.01
0.66 - - - - 4 0 .0 8 < 0.03 -
1.00 2.44 0.88 '1.39 0.84 0.05 0.03 <0.01 <,0.01
1.50 . - - - - - - <0.01 < 0.01
2.00 0.58 0.45 0.74 0.35 0.07 o.o4 0.01 < 0.01
2.50 - - - - - - 0.02 <0.01
3.00 0.41 0.20 0.36 0.18 0.11 0.06 0.03 -
3.50 - - - - - - 0.07 -
5.00 0.09 0.05 0.09 0.04 0.05 o.o4 o.o4 <0.01
6.00 - - - - - 0.03 I< 0.01
7.00 <0.04 <0.04 <0.04 <0.04 < 0.04 0.02 0.02 ' <0.01
8.00 - - - - - 0.02 I -
12.00 <0.04 <0.03 <0.03 < 0.04 - - - -
24.00 <0.03 <0.04 <0.04 <0.04 - - - —
All results expressed as jug meptazinol HCl/ml plasma
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' Table 8. Plasma concentration of unchanged meptazinol following oral 
dosage with 200 mg or intravenous dosage with 20 mg 
meptazinol to male human volunteers
Time after 
dosing 
(h)
Oral dosageIntravenous dosage
Subject E.M. 
Weight 70 kg
Subject L.B. 
Weight 76 kg
Subject J.S. 
Weight 70 kg
Subject J.B. 
Weight 64 kg
0.062
0.50
0.050
0.0311.00
0.0261.50 0.030
0.0270.0252.00
0.016 0.0193.00
6.00 0.007
8.00
0.0039.00
12.00
All results expressed as ug meptazinol HCl/ml plasma
NS = no sample
CHAPTER 6
STUDIES ON THE RATE AND EXTENT OF ABSORPTION 
OF MEPTAZINOL IN VARIOUS SPECIES.
I
Summary
Following the observation that much larger doses of the drug 
were required to elicit a biological -response when the compound was 
given orally as compared to parenterally, an investigation was made 
of the rate and completeness of absorption in various species. The 
efficiency of absorption was determined by a comparison of the extent 
of urinary excretion following oral or intravenous dosage of the radio­
labelled drug. An indication of the rate of absorption was obtained 
from the rapidity of attainment of peak plasma, levels.
The compound was almost completely absorbed in rats, monkeys and 
man as evidenced by the similarly,extensive urinary excretion following 
oral or intravenous dosage. However a species difference was observed 
with respect to the rate of absorption. Rats and mice absorbed the 
compound considerably more rapidly than monkeys or man. The signifi­
cance of this observation is discussed in relation to the biological 
activity of the drug.
Studies irr rodents
! -
(a) Experiments in rats - The rate of absorption of meptazinol in rats was
determined by measuring the rapidity of attainment of peak plasma concentra­
tions of radioactivity after orally administering a labelled dose of the
3 : -
compound. Thus groups of female or male rats received H labelled 
meptazinol at 23 mg/kg. Each group was killed at a different time after 
dosing and the blood collected individually from each animal. Total radio­
activity in the separated plasma was subsequently determined by liquid 
scintillation counting.
Assuming the route, of excretion was not altered by the dosage
route, the efficiency of absorption was determined by comparing the extent
of urinary excretion following oral or intravenous dosage.
•Three male and three female animals were dosed orally with labelled
meptazinol at 23 mg/kg. Urine was collected at intervals up to 7 days after 
dosing. A further two male and three female animals were dosed intravenously 
at 8 mg/kg and urine was collected at intervals for several days afterwards.
A comparison was then made of the amount of radioactivity in the 
urine samples obtained from each route of administration.
(b) Experiments in other rodent species. - In studying the rapidity of 
absorption of the compound in the mouse, groups of five male mice were killed 
at different times (and pooled blood collections made) up to 2 hours after 
oral administration of the labelled drug.
Radioactivity in the separated plasma was subsequently determined 
by liquid scintillation counting.
Studies in primates
(a) Experiments in monkeys - The absorption rate of meptazinol following 
its oral administration to monkeys was determined in a similar manner to that 
described for rats and mice. Thus two male and four female monkeys were 
given radiolabelled meptazinol orally at 23 mg/kg and blood samples taken at
was determined by liquid scintillation counting.
The efficiency of absorption of meptazinol in the monkey was 
estimated by comparing the extent of urinary excretion following oral or 
intravenous dosage of the drug. Thus two male and two female monkeys 
received the radiolabelled drug orally at 23 mg/kg and urine collections made 
at intervals up to five days after dosing. A further two male and t\*o
female animals were dosed intravenously at 8 mg/kg and again urine collection 
made at various intervals after dosing. A comparison of the amount of 
radioactivity (expressed as a % of the administered dose)found in the urine 
was calculated for each route of administration and this comparison revealed 
the extent of absorption of meptazinol/
(b) Experiments in humans - The rate of attainment of peak plasma concentrations 
of radioactivity was determined in two male human volunteers who each ingested 
200 mg of the labelled drug. Blood samples were taken at various times after 
dosing and aliquots of the separated plasma subjected to liquid scintillation 
counting.
The extent of absorption was determined by comparing the % of the 
administered dose found in the urine of the first two volunteers, with that 
found in the urine of a further two volunteers who each received an 
intravenous dose of 20 mg of the labelled drug.
Results
Studies in rodents
(a) Experiments in rats - Absorption in both male and female rats was very 
rapid as evidenced by peak levels of radioactivity being found in the plasma 
within 20 minutes of dosing. (see Tables 1 & 2 and Fig.. 1 ). A near
complete recovery of radioactivity was found in the urine after either oral 
or intravenous dosage of the drug showing it to be efficiently as well as 
rapidly absorbed, (see Kq O
seen within a very short time of dosing meptazinol to mice, peak levels 
being achieved within fO minutes of dosing (see Table 3 & Fig. 3)- Again 
absorption of the drug appeared to be very rapid.
Studies in primates ;
(a) Experiments in monkeys - Peak plasma levels of radioactivity were found 
by 2-3 h after dosing in the monkey showing the compound to be somewhat less 
rapidly absorbed in this species than in rats and mice (see Tables A & 3
& Fig. k). Absorption was near complete as evidenced by a similar percentage 
of the administered dose being found in the urine after oral or intravenous 
dosage (see Fig. 3)»
(b) Experiments in humans - Absorption of meptazinol was somewhat more rapid 
in this species than in the monkey but still considerably slower than in rats 
or mice. Peak plasma levels of total radioactivity occurred by 1-2 h after 
dosing (see Table 6 & Fig. 6). Again absorption of the drug was.almost 
complete as shown by the very similar recovery of. radioactivity in the urine 
by both oral and i.v. routes of administration. (see Fig.7).
Discussion
In common with other major analgesics, meptazinol is much less 
active orally than when given parenterally. This was particularly apparent 
in the monkey where there was no demonstrable analgesic activity after oral 
doses of meptazinol up to 80 mg/kg. In man also there was a very considerable 
difference between the effective oral and parenteral doses. In the case of 
other analgesics such as morphine and its surrogates this poor oral efficacy 
has previously been ascribed to the compounds being only poorly absorbed 
and because of this a study of the absorption of meptazinol in various species 
has been made.
The results have shown that meptazinol is in fact almost completely 
absorbed in all the species examined including the monkey. However there did 
appear to be a species difference with respect to the rate of absorption 
of the compound. In rats and mice where the oral/parenteral difference is 
not as marked as in monkey and man, the compound was very rapidly absorbed,
the absorption in man and particularly monkey was considerably slower, peak 
levels of radioactivity not being achieved until 1-3 hrs after dosing*
The inter-relationship of absorption and elimination rates on plasma 
drug concentrations
The level of any drug in the body depends on the relative rates 
of absorption and elimination. When the rate of absorption is only 
marginally more rapid than the rate of metabolism and excretion the 
result will be that only low blood and tissue levels are achieved.
This was the case with the experimental analgesic I.C.I. -^9^-33 (1-
I 1isopropyl 1,2,3,^-tetra hydro-carboline) such that the compound was 
found to be inactive in humans after its oral administration (Flanagan,
1969).
This concept may provide a satisfactory explanation for the 
relatively low oral potency of meptazinol in the monkey and in man. Certainly 
the drug is more slowly absorbed in these species which could lead to a 
'flattening out' of the plasma concentration/time profile such that only low 
levels of the drug would appear in plasma but these levels may be maintained 
for a relatively long period. The net result of this may be that the minimum 
effective plasma concentration required to elicit analgesia is never reached. 
Furthermore slower absorption could*- lead to more extensive metabolism of the 
drug. Meptazinol appears to be conjugated with glucuronic acid in all 
the species so far examined. Levy (1971) recently demonstrated that this 
glucuronide conjugation system v;as relatively easily saturated within the 
therapeutic dose range of several drugs. For drugs subject to extensive 
first pass metabolism . k-e vvj ^  : co k(yix*idl 'tkfkh.' ' substantial blood
levels would not be achieved until the breakthrough or 'saturation' dose 
level was achieved. Beyond this small increases in dose level would result 
in inordinate increases in plasma level. Thus the slower the rate of 
drug absorption the less likely that saturation concentrations of the drug 
in the portal blood, will be achieved.
In view of the . importance of the rate of meptazipol
absorption to its biological activity it is perhaps pertinent to mention some 
of the factors which could be responsible for the relatively slow absorption 
of the drug in monkeys and in man. • ;
1. (Bloodflow
• Drug absorption is considered to take place by a process of simple
diffusion, the speed of which will be determined by the concentration gradient. 
The blood flow in the region of the gastro-intestinal tract will necessarily 
influence the rate of removal and therefore the concentration gradient. While
I
it is possible that meptazinol may have some effect on blood pressure and 
therefore blood flow in monkeys and man this seems unlikely since studies in rats 
showed that at analgesic doses the compound did not cause any overt effect 
on blood pressure.
2. Drug/Food complexes
Drug absorption may be adversely affected by binding of the drug to 
food material in the gastro-intestinal tract. For example the absorption of 
tetracyclines is impaired in the presence of milk and milk products due to 
the formation of a complex with Ca^ !'. (Price et al, 1937) •
However such an effect is more likely to affect the efficiency,(rather 
than the rate, of absorption.
3. pH of the gastro-intestinal tract
Fundamental species differences in the intestinal pH could have a 
pronounced effect of the degree of ionization of the drug and thereby affect 
the rate and possibly efficiency of its absorption.
4. Gastric emptying rate
Drug absorption is thought to involve diffusion of unionized 
lipophilic drug molecules. For a weak base such as meptazinol, pKa 8.7? 
this will occur in the intestinal region of the G.I. tract where the pH is 
sufficiently high to allow at least a proportion of the molecules to exist in 
the unionized form and where the surface area of the gut wall is large enough
to encourage;absorption. Thus the rate of passage of the drug to its
I
site of absorption viz. small intestine, may be a major determinant 
of the drug's rate of absorption. Drug effects tending to delay this 
passage will necessarily reduce the rate of absorption. *
Thus delayed gastric emptying would be expected to reduce the 
rate of absorption of the compound. Mayersohn (1971) has drawn atten­
tion to the wide variety of factors which can affect gastric emptying 
such as temperature of the ingested material, its viscosity and osmotic 
pressure and also its volume. Indeed this volume factor may be 
involved in the, species difference in absorption rate and meptazinol 
since in monkeys and in man (where absorption is slower) the drug was 
given in either a smaller vehicle volume, 5 ml/kg for the monkey or 
as a solid in the case of humans. Rats and mice received the drug in 
a vehicle volume of 10 ml/kg.
» J
oral administration of 23 mg/kg H meptazinol
Time after dosing 
(h)
Plasma concentrations Mean
0.33
6.67
1.00
2.00
4.00
6.00
8.00
16.00
24.00
12.09, 17.00, 13.16, 3.83 
17.63, 9.23, 10.62, 6.01 
12.07, 6.43, 3.17, 3.17 
4.62, 3.78, 3.24, 3.11 
.2.13, 2.89, 1.98, 3.83 
2.72, 3 .10, 2.91, 2.30 
3 .69, 3 .86, 1.72, 3.123 
2.48, 2.31, 2.46, 2.49 
2.03, 2.13, 1.41, 1.97
12.02
10.88
7.21
3.68
2.71
2.73
3.09
2.43
1.88
Table 2 - Radioactivity levels found in the plasma of male rats following
oral administration of 23 mg/kg H meptazinol
Time after dosing Plasma concentrations 
(h) |
Mean
0.33 20.76, 14.10 17.^3
0.67 13.20, 16.32 14.76
1.00 10.36, 8.32 9.44
2.00 4.39, 6.06
\
3-33
4.00 M 3 '4.93
6.00 5.91, 5.58 3-73
8.00 k.77, 5.02 4.90
16.00 M 5 ,  - 4.93
24.00 4.26, 4.75 4.31
N.B. All results expressed as i^g equivalents meptazinol HCl/ml plasma
Fig- 1.
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Table 3. - Radioactivity levels found in the plasma of male mice following
1 / 14oral administration of 25 mg/kg C meptazinol
Time after 
dosing 
(h)
Plasma concentration* 
(ug equivalents meptaz- 
i'nol HCl/ml)
0.33 8.82
0.67 12.43
1.00 7.65
2.00 2.78
4-. 00 1.12
6.00 0.35
7.50 0.61
13-00 0.57
24.50 0.41
^determined from pooled blood samples collected 
from groups of five mice.
Rate of absorption of-Meptasino!
 ■■Ill .        I ilia | | HU HI I I H
by mtce
Totai radiocarbon /eveis found 
in the p/asma of mate mice 
after ora/ administration BSmglkg 
Meptazinol HC/.
Table 4. Radioactivity levels found in the plasma of female monkeys
after oral administration of 23 mg/kg meptazinol
Time after dosing 
(h)
Monkey 1 
%
•
Monkey 2 
14C
Monkey 3 
14C
Monkey 4
3H
0.25 0.08 5.35
0.33 0.35
0.50
/
0.24 6.51 0.11
0.67 0.30 0.69
1.0 7*90 12.40 5.06
1.5 1.31
2.0 24.16 22.35 26.05 5.63
2.5 • 11.96
3.0 10.15 11.45 44.56 15.94
3-5 28.60
4.0 8.12 8.84 I
■5.0 5.39 19.21 24.41
6.0 4.45 3-94 15.00
7.0 3.90 6.46 9.67
8.0 3.80 7.25
12.0 3.57 1.98 • .
24.0 3.28 0.35
All results expressed as ug equivalents meptazinol HCl/ml plasma
Table 5 - Radioactivity levels found in the plasma of male monkeys
I
after oral administration of 25 mg/kg meptazinol
Time after dosing 
(h)
Monkey 1 
V
Monkey 2 
14
c
Monkey 3 ; 
14
C
0.25 ' 2.5^ 2.36
0.33
*
3.24
0.50 3.02 .2.48
0.67 6.03
1.0 4.20 4.51 11.17
1.3
2.0 23:48 2.6.14 18.91
2-5'
3.0 20.77 16.14 30.92
3.5
4.0 12.74 11.66
5.0 8.62 19.09
6.0 5.71 5.09
7.0 4.39 6.04
8.0 3.62
12.0 3.63 1.90
' 24.0 | 
!
3-28 O .58
All results expressed as ug equivalents meptazinol HCl/ml plasma
— y ,r- T ..»" 'I T'" i" 1 r..\ ' 1 i '
& $ N- o
~  *\| <\| C\| ^  ^
ou/so/d /UJ/o/y /ou/zofday/ SAinbz 6rf
r K
\o
-  ^
- f\J
b- rs o
- NO
-
* >
-
- <\l
Ho
ur
s 
af
te
r 
do
si
ng
% 
ad
mi
ni
st
er
ed
 
ra
di
oc
ar
 d
on
 
% 
ad
mi
ni
 s
te
re
d 
ra
di
oc
ar
bo
n
fo
un
d 
in 
ur
in
e 
fo
un
d 
in 
ur
in
e
of absorption of Meptazinol in
monkeys
After oraf administration After intravenous a dm in­
to female animats (25mgjkg) isfration to female
animals (8 mg!kg)
F  228
F  225
01 b— —-
F227
F 226
40
20
After ora/ administration After intravenous admin -
to male animals (25mg!kg) isfration to male animals
(8 mg I kg)
M  219 
A — — AM2I7
A  *, -— A
M  220
24 48 72 96 24 48 72
Hours after dosing
Table 6 - Radioactivity levels found in the plasma of male human •
volunteers after oral ingestion of radiolabelled meptazinol
Time after dosing 
(h)
Subject J.B. | Subject E.M.
0.50 1.71 2.06
00• 7.27 ■ 5.84
2.00 6A 9 5.97
13.00 4.9 7 4.86
/
'4.00 4.06 3.50
6.00 2.42 1.82
8.00 1.81 1.27
12.00 1.22 0.95
• 24.00 0.59
i
0.46
i
All results expressed as ug equivalents meptazinol HCl/ml plasma
Total radiocarbon levels 
found in the plasma of 
male volunteers after oral  
administration of approx.
3 mg/kg meptazinol HCI
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of approx.0 -3  mg/kgSubject J.B.
Subject J.S.70-s — © --------- <£*-------
Subject E.M.
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40
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CHAPTER 7
INVESTIGATIONS INTO THE FACTORS RESPONSIBLE FOR 
THE SPECIES DIFFERENCE IN PLASMA LEVELS OF MEPTAZINOL 
FOLLOWING ITS ORAL ADMINISTRATION.
Summary
The results of an in vitro assay for meptazinol glucuronyl 
transferase in monkey and rat liver showed similar enzyme activities 
in both species. It therefore seemed unlikely that the explanation 
for the lower plasma levels of the drug observed in the monkey after 
oral dosage was due to a greater enzyme activity in this species.
Investigation into the influence of gastric emptying in the 
monkey^ on meptazinol absorption and resultant plasma levels^ showed that 
when the drug was instilled directly into the duodenum more rapid 
absorption ensued and very much higher plasma levels were achieved.
This increase in the concentration of unchanged meptazinol appeared to 
be at .least partly due to saturation of the conjugation mechanism since 
the proportion of meptazinol to its glucuronide was greater.
Further studies showed there to be a fundamental difference in 
normal gastric emptying time between the monkey and the rat, emptying 
being considerably slower in the monkey. In addition meptazinol was 
shown to have a retarding action on gastric emptying in the monkey but 
no similar effect was seen in the rat.
The relevance of these observations to man is discussed.
in rats and monkeys.
Introduction
The observations made in the preceding chapter suggested that a 
major factor involved in the species difference in plasma levels resulting 
from oral administration may be the rate of drug absorption. This will 
be controlled by several factors, one of the most important being gastric 
emptying. However before embarking upon a study of the influence of 
gastric emptying on the drug's absorption rate it was felt necessary to 
eliminate (or otherwise) the possibility that this species variation in 
plasma level was not merely due to a difference in enzyme activity 
(glucuronyl transferase). Accordingly studies were carried out to 
compare the hepatic glucuronyl transferase activity in rats and monkeys. 
Materials
H meptazinol hydrochloride, specific activity 5»5 ^Ci/mg was 
supplied by the Medicinal Chemistry Department, Wyeth Laboratories, U.K. 
Uridine 5 1-diphosphoglucuronic acid, ammonium salt (UDPGA) was obtained 
from Sigma Chemical Company Limited, London.
Methods
(1) Isolation of microsomes
Female Sprague-Dawley rats weighing 250-300 g were used. The 
animals were starved overnight and then killed by cervical dislocation. 
Female Red Patas monkeys 3-5 kg were also starved overnight but were 
killed by intravenous injection of saturated magnesium sulphate solution.
The livers were removed as quickly as possible after death and crude 
homogenates (18% w/v) prepared in 1.15^ KC1 by masceration using an M.SE. 
liquidizer (M.SE. Crawley, Sussex). A finer homogenate was then prepared 
by use of a Potter-type homogenizer. Hepatic microsomes were isolated 
in a manner similar to that described by Baron & Tephly (1970). Briefly, 
the homogenate was centrifuged at 9000 g for 20 minutes at 0-V3 in an 
M.SE. High Speed 25. centrifuge to sediment unbroken cells, nuclei and 
mitochondria. The post mitochondrial supernatant was then centrifuged
txu i w i , www £  xwx -y\j 1UXHU.1/C0  uu ocuxmcui- out: iii.LUi'U£>UincU_ XI'clC 1,1011. Xne
microsomal pellet was washed by resuspending in 1.15% KC1 and centrifuged
i
once more for 90’minutes at 10A,000 g. The microsomal pellets thus
prepared were stored under nitrogen at -50° until required.
(2) Assay of glucuronyl transferase activity
A method similar to that described by Sanchez & Tephly (197^) for
the assay of morphine glucuronyl transferase was adopted. The standard
3
reaction mixture was composed of 0.01 - 10.00 mM H meptazinol hydro­
chloride; UDPGA, 3-0mM; MgCl^, 3-0mM; Tris HC1 30mM pH 7.6; 3 ~ 5 mg
microsomal protein (protein was measured by the method of Lowry et al 
(1951)• The total volume was 2.0 ml. The mixtures were incubated 
aerobically, with shaking, at 37°• The reaction was initiated by the 
addition of the microsomal protein and terminated after 20 minutes by 
the addition of 1.0 ml 7-3mM lead nitrate solution. Zero time blanks 
were prepared by adding 1.0 ml lead nitrate solution at the same time as 
the addition of the microsomal protein to the reaction mixture.
Measurement of the amount of meptazinol glucuronide formed, was 
accomplished after first removing residual unchanged drug. To optimize 
the removal of the drug each reaction mixture was spiked with 0.3 ml 20mM 
meptazinol hydrochloride. The reaction mixture was then basified by the 
addition of 1.0 ml of 1.0M bicarbonate buffer pH 9-6. Extraction with 
3 x 13 ml of toluene was found to remove 98.7^ +. 0.09 SEM^ of the 
unchanged drug. 1.0 ml aliquots of the remaining aqueous phase, 
containing the glucuronide were subsequently taken for radioassay. 
Experimental
\
(1) Studies in rats
The reaction velocity of rat hepatic glucuronyl transferase towards 
meptazinol was determined over substrate•concentrations ranging from 0.01mM 
to 10.00mM. Assays were performed in triplicate on microsomal prepara­
tions from two rats.
The reaction rate of m o n k e y  hepatic glucuronyl transferase, 
towards meptazinol was measured at substrate concentrations varying 
from 0.01mM to 10.0mM. Assays were performed in triplicate on micro­
somal preparations from two monkeys. ;
Results and discussion
An exhaustive search of the scientific literature revealed that 
relatively lttle had been done by way,of comparative studies on rat and 
monkey glucuronyl transferase. One report by Lathe & Walker (195?) 
showed that the activity of glucuronyl transferase towards 0_ aminophenol 
was similar in both rat and monkey liver. However extrapolation of this 
observation to meptazinol conjugation could not justifiably be made since 
recent studies have shown there to be more than one glucuronyl trans­
ferase. For example Sanchez and Tephly (197^) have presented evidence 
for the existance of separate enzymes involved in the conjugation of 
morphine and of p nitrophenol by rat liver. In view of these findings a 
direct comparative study of meptazinol glucuronyl transferase activity in 
rats and monkeys was warranted.
The results have shoirn the existence of a relatively active system 
for the conjugation of meptazinol in the livers of both species. The V 
was similar in both rats and monkeys being about 2.5n Moles meptazinol 
glucuronide formed/mg microsomal protein/minute. (See table 1 & _fig.-l)This was 
approximately three times greater than that found'by, Sanchez- & Tephly(197^)for rat 
hepatic morphine glucuronyl transferase. The substrate concentrations 
at which meptazinol glucuronyl transferase appeared to reach a maximum 
was similar in rats and monkeys being approximately 0.5mM.
The results of the comparative study suggest that the explanation 
for the lower plasma level of unchanged meptazinol in the monkey (following 
oral administration) was not due to a fundamentally greater hepatic 
glucuronyl transferase activity in this species. There does however
remain the possibility that there may be a greater species difference 
in the intestinal glucuronyl transferase although del Villar et al 
(197^) have shown the rat intestinal glucuronyl transferase system to 
be much less active than that found in the liver.
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SUBSTRATE CONCENTRATION (mM) 
!-----------IS_________„ 2rQ.„ AO
MEPTAZINOL GLUCURONYL TRANSFERASE ACTIVITY IN MONKEY 
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Part 2. The influence of gastric emptying rate on plasma levels of 
meptazinol in various species 
Introduction '
The results of studies on the absorption of meptazinol in various 
species indicated a correlation between slower absorption and lower 
plasma concentrations of the unconjugated drug (see Chapter 5)» Since a 
major determinant of the absorption of a weakly basic drug may be gastric 
emptying, the influence of this process on the absorption and plasma 
kinetics of meptazinol was investigated. The effect of stomach 
emptying on blood levels of the compound was studied in the monkey by 
comparing plasma concentrations of the drug resulting from normal gastric 
intubation with those from direct instillation into the duodenum.
Methods
Implantation of the duodenal cannula into the monkey
Surgical implantation of a small duodenal cannula was performed
in two female Patas monkeys each weighing approximately 3kg. Each animal
*
was sedated with Sernylan i.m. and then anaesthetized under halothane.
After shaving the abdominal region a mid-line incision was made to expose
the gastrointestinal tract. Taking care to minimise the disruption of
the mesenteric tissue and associated vasculature the duodenal region was
exposed and a small incision made. The open end of a plastic cannula
(Portex, disposable manometer line, type 200/^-90/100) was then introduced
into the duodenal lumen and the incision subsequently closed by ’purse-
string’ stitching. To reduce the likelihood of the cannula coming out
it was further secured to the exterior of the pyloric region of the stomach.
The other end of the cannula which was closed by a small rubber .septum
was then exterioized through the peritoneum and fastened beneath a fold
of skin towards the animals groin. This wound and the main abdominal
entry incision were closed and dusted with sulphanilamide. During the
first week the animals were dosed daily with penicillin/streptomycin.
A photographic record of the various stages in this operation is shown in 
fig. 2.
^Phencyclidine hydrochloride
Each animal was allowed to recover for two to three weeks. The . 
implantation of the cannulae did not appear to adversely affect the 
animals in any obvious way. Food consumption, body weight and general 
behaviour seemed normal. There was no evidence of altered gastro­
intestinal motility since the animals did not suffer from constipation 
or diarrhoea. . , , . . • ■
Experimental
Two female monkeys with permanently implanted duodenal cannulae
* -z
were dosed intraduodenally with H meptazinol at 23 rag/kg (vehicle volume,
3 ml i/sotonic saline/kg body weight). Blood samples were collected from 
a femoral vein for up to 7 hours after dosing. Several days later each 
animal received an oral dose of the drug at the same dosage and 
vehicle volume. Again blood samples were taken for several hours after 
dosing. The plasma was separated and after basification extracted with 
toluene sc’intillant to remove the unchanged drug as described in Chaper 2.
Radioassay of these extracts enabled the concentration of meptazinol 
to be calculated. The radioactivity in the residue remaining after 
extraction, which would represent polar metabolites, was also determined.
Results The results are presented in tables 2 and 3 & fig.3.
Intraduodenal dosage of meptazinol to these monkeys resulted in
very rapid absorption, peak plasma levels being observed within 13 mins.
of dosing. After intra-gastric dosage, peak- concentrations were not seen
until 2.3 - 3-3 h afterwards. Associated with this more rapid absorption
following intraduodenal dosage were plasma concentrations very much higher
than after oral dosage. Maximum plasma concentrations of free meptazinol
after intraduodenal dosage ranged from 300 - 800 ng/ml, compared to 13-68
ng/ml after the same dose was given orally. Considerable inter and intra
variation was seen with respect to the "apparent" peak plasma level of
the drug after intraduodenal dosage. This effect has previously been
observed in rats where absorption was very rapid. When absorption
proceeds extremely rapidly small variations in the rate of this process
*by injection through the rubber septum attached to the proximal end 
of the duodenal cannula
w i ± ±  i e a a  1:0 a p p a r e n c y  l a r g e  v a x -± a u ± u i i tD  x.11 p x a s in a  x e v e i  01 u n e  a r u g  
even though the actual peak levels may be very similar.
Discussion
The monkey has been used as a model to investigate the influence 
of gastric emptying on the magnitude of the plasma levels produced after 
oral administration of meptazinol. Avoiding the influence of gastric 
emptying altogether by instilling the drug directly into the duodenum 
has shov/n that very much higher levels of unchanged drug appear in the 
blood. At first sight, two explanations for these observations would 
seem likely. The drug might be chemically unstable under the acid 
conditions existing in the stomach and thus intraduodenal administration, 
by avoiding this problem, would be expected to lead to higher plasma levels. 
However stability studies have indicated that the drug is not subject to 
degradation under acid conditions. This leaves the second explanation of 
more rapid absorption resulting in saturation of the conjugation mechanism, 
to be the most likely cause. More rapid absorption is indeed indicated 
by the attainment of peak plasma levels within 0 .33 h after intraduodenal 
dosage as compared to £.3 - 3*5 h after oral administration. Evidence 
for saturation of the conjugating mechanism is to be found in the higher 
proportion of unchanged drug relative to metabolites seen after intra­
duodenal dosage.
Other workers have previously demonstrated the influence that gastric 
emptying can have on the magnitude of plasma drug concentrations. For 
example Heading et al, (1973) showed a good correlation between gastric 
emptying time (measured radiographically) and peak plasma levels of 
paracetamol in humans. The more rapid the rate of emptying the higher 
the peak plasma levels observed. Like meptazinol, paracetamol is a drug 
subject to extensive first pass metabolism. Cohen et al (1973)? in- 
studying the first pass metabolism of paracetamol by the isolated perfused 
rat liver showed that the hepatic extraction ratio for the drug decreased 
with increasing concentrations of the drug in the perfusion fluid. They
of drug in the portal vein, could influence the amount of first pass 
metabolism and presumably therefore the peak plasma level. This may 
provide an explanation for Heading’s results and may be equally applicable 
to meptazinol. !
Further evidence from the literature of the importance of gastric 
emptying rate on plasma drug levels is provided by a report of Goto 
et al (1972). They were able to show that the increased plasma levels 
of aminopyrine in the rabbit resulting from combination of the drug with 
barbital was due to the action of barbital in reducing the inhibitory 
e f f e c J  o f aminopyrine on gastric emptying.
By analogy with these examples it appears that gastric emptying 
may be a major determinant of the extent of first pass metabolism of 
meptazinol and therefore the plasma level of the unchanged drug.
j- J- uiatici.iu ^aiiiiuiaL.i.un kj x. llic umiiixc-y uu.uuci.i.um
Implanting plastic cannula into 
duodenum showing ’’purse string 
stitching used to pinch grip the 
cannula.
Stage 3
Anchoring cannula to 
the outside of the 
stomach wall. Photograph 
also shows rubber septum 
at the exterior end of the 
cannula.
Stage 4
Stage 1 Stage 2
Exteriorizing cannula through 
peritoneum showing further 
point of anchorage.
Operation completed. 
Photograph shows outline 
of septum sandwiched 
between skin and body wall.
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in traduodenal or oral administration' of Meptazin ol at 2 5 mg/kg 
to two female monkeys.
60-,
onke
5 0
Unchanged drug Total radioactivity
0 - 4 - 1 © after intraduodenal 
dosage
A after oral dosage
0-3 3 0 -
20 -
1 0 -
i J&BBFfBsrsirxsezpxs:
Monkey 237 ?
mii imu mini
100 -,1-0
Unchanged drug Total radioactivity
0-6
c> 40-
0 -2-j £20
Time after dosing (hrs)
•me enecx 01 meptazinol on gastric emptying in rats and, monkeys
Introduction
Data presented in the preceding section has shown the influence 
of gastric emptying in determining the plasma levels of this drug- The 
question remained as to how precisely this process was involved in the 
species difference observed in plasma concentrations of the drug. For 
example was the rate of emptying fundamentally much slower in the larger 
animals or were these species just more susceptible to any inhibitory
effects the drug may have had on gastric emptying? In order to answer
.
these questions a comparative study between rats and monkeys was carried
out to determine the rate of gastric emptying and the influence of
meptazinol on this process- Gastric emptying was determined by measuring
1
the disappearance of the unabsorbable radiolabelled markers, C PEG f^OOO 
3
and H inulin from the stomach.
Experimental
Measurement of gastric emptying in the rat
Groups of eight male rats weighing 250-330g received 3 ml of 
isotonic saline containing 1p. Ci C polyethylene glycol ^000 and 3,u Ci H 
inulin (Radiochemical Centre, Amersham, U.K.) following overnight fasting. 
Water was withdrawn 1h before the study. Groups were killed at 10, 20 
or 30 minutes after- dosing by injecting ethanol directly into the brain.
This technique produced death almost instantaneously and avoided the 
convulsions normally seen after cervical dislocation so enabling the rapid 
dissection and removal of the stomach. Each stomach was clamped at the 
pyloric and oesphageal ends prior to its removal. The contents were 
washed out with saline and aliquois subjected to liquid scintillation counting. 
Since gastric emptying of a liquid appears to be a first order process the 
rate of emptying could be conveniently expressed in terms of a half life
determined from a plot of dose remaining in stomach against time.
After establishing the rate of gastric emptying under these conditions the
influence of meptazinol was investigated. 8 mg unlabelled meptazinol was
1 4added to each 3 ml of isotonic saline containing C PEG 4000 and the 
gastric emptying rate re-examined.
Measurement of gastric emptying in the monkey
A group of four male monkeys were starved overnight. The
following morning each animal received 13 ml isotonic saline containing
'iL .
3u Ci C PEG 4000. 30 minutes afterwards, while the animals were restrained,
 ^ \ ' . 
their stomachs were washed out with 3 x 30 ml isotonic saline and the amount
of radiolabelled marker present determined by liquid scintillation counting
of appropriate aliquots. Assuming disappearance of the marker from the
stomach,to proceed in an exponential fashion the half life of emptying was
calculated from the expression t\ - 0.301 x t
log n (xo)
* (xt)
where t = time after dosing, in this case 30 minutes.
xo = % remaining in stomach at time 0 = 100$
' xt = % remaining in stomach at time t.
After establishing the normal rate of gastric emptying the influence of
meptazinol (given at 23 mg/kg p.o.) on this process was investigated.
Results
Studies in the rat
The results presented in table 4 show that the disappearance of
14C PEG 4000 from rat stomach proceeded in an exponential fashion. The 
half-life for gastric emptying under normal conditions was found to be 
8.3 mins. The presence of meptazinol at 23 mg/kg p.o. appeared to have 
no significant effect on gastric emptying in this species.
Studies in the monkey
The normal rate of gastric emptying in this species was shown to be 
considerably slower than in the rat, see table 3 - A half life of approx. 30 
mins. for gastric emptying in the monkey was found compared to approximately 
9 mins. in the rat. Furthermore unlike the situation in the rat, meptazinol had
after 25 mg/kg p.o. the half life was increased from 30 to 60 minutes.
Discussion
14
A semi-logarithmic plot of gastric retention of C PEG 4000 
versus time in the rat indicated that gastric emptying proceeded by 
apparent first order kinetics. This finding is consistent with the 
results of Hunt & McDonald (195^) from studies in humans, who showed that 
the stomach content volume of a liquid test meal decreased in an exponential 
manner with time. The present investigations have shown a half life value 
of 8.5 mins. for gastric emptying in the rat, a figure in fairly good agree­
ment with that observed by Feldman et al (1968) of 10.5 13 mins. Meptazinol had
apparently no effect on gastric emptying in this species when given at 
25 mg/kg p.o.
Studies in the monkey revealed a much slower rate of emptying 
than was seen in the rat, t-he half life being approx.. 30 mins. This 
observed rate of emptying agrees well with that seen in Rhesus monkeys by 
Jacoby & Brodie, (1968). In addition the monkey appeared to be more 
susceptible to the inhibitory effects of the drug on gastric motility, 
the half-life of gastric emptying being doubled in the presence of the 
drug given at 25 mg/kg p.o.
The pharmacological mechanism involved in delaying gastric 
emptying remains a matter for speculation. It has been suggested that the 
retarding actions of other analgesics on gastric motility may at least be 
partly due to their anticholinergic properties. However meptazinol would 
appear not to possess any such property, at least in the guinea pig, since 
it failed to depress the twitch caused by ace.fyl ckolitj£. . 0
On the contrary meptazinol has been shown to have weak cholinergic 
agonist activity actually potentiating the response of electrical stimula­
tion of the guinea pig ileum. Despite these observations there remains 
the possibility that the drug may exhibit a different qualitative 
pharmacological profile in the monkey.
involving the,'local anaesthetic activity of meptazinol. Although only
weakly active - it has approx. 1/I0th potency of lignocaine in the guinea
pig weal test - the relatively high local concentration is the stomachy
—2
equivalent to 0.2 - 1.0x10 M would, (on the basis of studies in the guinea 
pig), produce local anaesthesia from 15-30^. This effect may well be more 
pronounced in the monkey since the longer normal gastric emptying - and 
therefore longer residence time of the drug in the stomach - would facilitate 
any penetration and uptake of the drug that may occur. Varga, (1966) has 
suggested that the effect of chloroquine in delaying gastric emptying in the 
rat may be due to the local anaesthetic activity of the compound. Further­
more he showed that the consequence of this delayed gastric emptying was a 
lower toxicity than when the drug was instilled directly into the small 
intestine. This was presumably due to the more extensive detoxification 
resulting from the slower absorption of the compound.
Whatever the pharmacological explanation for the delayed gastric 
emptying caused by meptazinol, the indication remains that the resulting 
slower absorption of the drug leads to more extensive metabolism and 
consequently relatively low plasma levels. Thus in the monkey in which 
gastric emptying time is normally relatively long and in which meptazinol 
has a marked retarding action on gastric motility, the first pass conjugation 
of the drug is likely to be very extensive.
An examination of the scientific literature shows that gastric 
emptying time in man is at least as long as that observed in monkeys. For 
example van Dam (197*0 studied the emptying time in 30 normal volunteers and 
found a mean half life of by mins, range 22-77 mins. This is close to 
values obtained by other investigators. Griffiths, (1966) reported a value 
of 70 mins,Fridrich,(1970), 6k mins and Harvey,(1970) 36 mins. In view of 
this relatively slow gastric emptying in man it is possible that the low oral 
potency of the drug in this species may be explained in similar terms to 
that postulated for the monkey.
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lame ?. mrluence or meptazinol on gastric emptying in female monkeys
Experiment 1
Monkey
No.
(
Undosed control j 
group 7o remaining' 
in stomach after !,
30 min. f1
(min)
Dosed (25 mg/kg) 
group 7. remaining 
in stomach after 
30 min.
(min)
284
i
63.40 | 45.62 71.46 61.88
285 I
- ?
48.23 |
1
26.21 80.72 97.07
i
1 286 . 58.74 j 39.08 80.35 95.04
) 287'
!
54.14 1s 33.89 . 69.96 58.20
1 Mean + SEM = !
1
|
36.20 + 4.10 = 78.04 + 10.43
Experiment II
284
■j
48.94 I 29.95 57.15 37.16
285 37.29 j 21.07 54.07 33.81
286 48.66 | 28.87 77.65 82.20
287 39.63 | 22.46 65.56 49.25
Mean + SEM = |
! I1 i
25.59 + 2.24 50.60 + 11.04
The values from a single time point were calculated using the formula
= 0.3Q1 x t which assumes monoexponential disappearance 
log,n(xo) of substance from stomach.
(xt)
where t = time point (30 min) xq = 7« remaining in stomach at time 0
= % remaining in stomach at time t
CHAPTER 8.
ATTEMPTS TO CIRCUMVENT THE PROBLEM OF EXTENSIVE 
FIRST PASS CONJUGATION OF MEPTAZINOL.
Summary
Attempts to increase the 'oral1 potency of meptazinol by 
circumventing the problem of first pass conjugation involved four separate 
approaches - ;
(1) Esterification of the phenolic function of the drug in the hope of 
providing some initial protection against conjugation of the hydroxyl 
function.
(2) Competitive inhibition of the glucuronic acid conjugation mechanism 
by the co-administration of other compounds sharing this pathway.
/ n i ' ' 'K3) Stimulation of gastric emptying in order to facilitate more rapid 
absorption and thereby saturate the conjugation mechanism.
(^ f) Rectal administration to avoid the problem of slow absorption resulting 
from delayed gastric emptying.
The monkey was chosen as the most suitable animal model since it 
appeared to closely resemble man in the handling of the drug.
Neither the acetate nor the heptanoate ester showed any advantage 
over administering meptazinol itself. Plasma levels of free meptazinol 
were no higher than when the unesterified drug was given.
Co-administration of meptazinol with paracetamol, aspirin or 
salicylamide also failed to elevate the plasma levels of free meptazinol.
Attempted stimulation of gastric emptying by the use of metoclopra 
mide did in fact increase the rate of absorption.but not sufficiently to ( 
produce increased levels of meptazinol.
Rectal administration was found to be the most successful means of 
increasing the drug’s potency. Plasma levels 5 to 10 times those seen afte 
giving the same dose orally were found. Studies in humans showed similar 
results.
-L110X U U U U  t/XUXl
Studies in animals and man have shown that meptazinol is subject to 
extensive first pass metabolism and in consequence has only a relatively low 
oral potency in contrast to that of the i.v. route. This first pass effect 
is most marked in monkey and man probably due to the relatively long gastric 
emptying time and consequently slow absorption of the drug. In man effective 
analgesia is only produced after oral doses in excess of 2^0 mg and in view 
of the high synthetic cost of the drug much effort was put into finding ways 
of increasing the drug's potency. To facilitate this work the monkey was 
chosen as the most suitable model since it closely resembled man in the 
disposition of this drug. A number of different approaches were adopted 
in attempting to overcome the problem of extensive first pass conjugation.
(1) Molecular modification
Metabolism of meptazinol occurs by the rapid conjugation of the . 
phenolic hydroxyl function with glucuronic acid. Temporary blocking of this 
site, by^  for example, esterification, might afford some protection from 
metabolism during the drug's initial passage through the liver. Once in the 
systemic circulation the active drug should be regenerated by the action of 
plasma esterases. The use of so called prodrugs to improve bioavailability 
of drugs is not a new concept. For example, the bioavailability of 
epinephrine, used in the treatment of glaucoma, has been improved many fold 
by making the dipivalate ester (McClure, 197*0• A further example of 
esters being used as prodrugs is to be found in the anti-leukemic drug; 
cytarabine. The metabolic deactivation of this compound was shown to be 
slowed down by the formation of its 5 ' ester with adamantoyl carboxylic acid
ehc\l
(Gish, 1971)• Thus in view of these examples of the successful molecular 
manipulation to improve bioavailability, the acetate and heptanoate esters 
of meptazinol were prepared and plasma levels of free meptazinol present 
after their oral administration determined.
It; is evident that a number of important drug biotransformation
i
processes, such as the mechanism for conjugation, have a relatively limited 
capacity and can be saturated within the normal therapeutic range of some 
drugs. Co-administration of drugs sharing the same metabolic pathway has 
been shown to lead to a mutual inhibition of metabolism. For example Levy 
& Procknal (1968) showed that co-administration of salicylamide and sodium 
salicylate to healthy adult volunteers resulted in a pronounced decrease in 
the amount of glucuronide of each drug formed. Similarly when salicylamide 
was given with paracetamol a mutual inhibitory effect on sulphate/glucuronide 
formation was observed with a corresponding reduction in the excretion rates 
of the two drugs' (Levy & Yamada, 1971).
In the light of these observations the effect of combining meptazinol 
with other analgesic drugs such as salicylamide,aspirin or paracetamol on the 
plasma levels of meptazinol was investigated.
(3) Stimulation of gastric emptying
In order to facilitate the more rapid absorption of the compound 
and hopefully thereby increase the plasma levels of the drug attempts have 
been made to stimulate gastric emptying by the co-administration of metoclop- 
ramide. This compound has been shown to significantly accelerate the gastric 
emptying of a barium meal given to monkeys (Jacoby, 1967).Furthermore meto- 
clopramide has been successfully used to increase the rate of absorption and 
peak plasma levels of paracetamol given to subjects known to be consistently 
slow absorbers of paracetamol (Nimmo et al, 1973).
Thus the influence of metoclopramide on plasma levels of meptazinol 
was investigated. A further potential advantage of such a drug combination 
could be the potent anti-emetic properties of metoclopramide which would 
counteract the nausea and vomiting occasionally reported after meptazinol 
treatment.
(^ f) Rectal administration.
Rectal' administration of meptazinol may provide an alternative 
means of avoiding the problems of relatively slow gastric emptying and 
absorption. In addition, although the larger proportion of the dose 
will still pass to the portal system, a small proportion will avoid the liver 
at the first pass, being absorbed directly into the systemic circulation 
through the inferior haemorrhoidal veins. Burt & Beckett (1971) have shown 
that the analgesic pentazocine is well absorbed following rectal 
administration.
In the light of these observations, studies were undertaken to 
determine the plasma levels of meptazinol produced after rectal administration.
Approach (l)i
j ' ' * ‘
Studies on some esters of meptazinol 
Preparation of the esters
The acetate and heptanoate esters of meptazinol were prepared by 
Dr. A. White, Medicinal Chemistry Department, Wyeth Laboratories (U.K.) by 
treating the randomly tritiated free base of the drug with the corresponding 
acid chloride. The radiochemical purity of the esters was greater than 9 
as shown by thin layer chromatography and the specific activities were approx. 
"35 yu Ci/mg for the heptanoate and 50 yu Ci/mg for the acetate. These esters 
were chemically stable under acid conditions but hydrolyzed slowly above
pH9-
In vitro hydrolysis of esters
The rates of hydrolysis of the acetate heptanoate esters of 
meptazinol by rat plasma esterases were determined spectrophotometrically. 
Since the esters exhibit negligible ultra-violet absorption at 275 urn relative 
to meptazinol itself the rates of hydrolysis can be followed spectrophoto­
metrically by measuring the formation of the drug. Plasma (100 ^ il) was 
added to 3*5 ml of a 500 ^ ig/ml solution of the ester (in a pH 7.^ phosphate 
buffer) in a cuvette. The reference cell contained buffer and 100 ^ il plasma. 
Both reference and sample cells were maintained at 37°• The formation of 
meptazinol was measured at 275 nm in a Pye Unicam SP700C spectrophotometer 
for up to 20 minutes after the initiation of the reaction.
In vivo hydrolysis of esters
Plasma levels of meptazinol achieved after oral administration of 
the acetate or heptanoate esters were determined. Gelatin capsules 
containing 75 mg of the acetate or the heptanoate were prepared^ using 
lactose as a filler. Two male and two female monkeys were starved 
overnight and then given a capsule of either the acetate or the heptanoate. 
Heparinized blood samples (3 ml) were taken for up to 7h after dosing. The
plasma was separated and toluene soluble radioactivity, which would include
i
the parent ester and any meptazinol derived from it, estimated by liquid 
scintillation counting. *
Results and Discussion
The results of in vitro studies using plasma showed the acetate 
to be much more rapidly hydrolyzed than the heptanoate (see fig.1). In 
addition the hydrolysis of the heptanoate ceased abruptly after only three 
minutes (product inhibition?) whereas the rate of hydrolysis of the acetate 
proceeded in a linear manner for at least '[k mins.
Despite the differences in the in vitro behaviour of these esters, 
in vivo studies showed them to behave very similarly (see tables 1 and 2). 
Both compounds were well absorbed but from the low plasma levels of free 
meptazinol and the esters, rapid hydrolysis to meptazinol and subsequent 
conjugation appears to have occurred. This hydrolysis was probably due to 
esterase action rather than simple chemical degradation since both esters 
were shown to be stable over the physiological pH range (1-8).
Thus it appears that neither of these esters offers any advantage 
over meptazinol itself. • However it is possible that longer chain esters 
would prove more useful since these are likely to be hydrolyzed more slowly. 
For example Bauguess et al (1975) showed that the rate of hydrolysis of 
phenolic esters of paracetamol was inversely proportional to chain length of 
the fatty acid. However longer chain esters become'increasingly hydrophobic 
and may be insufficiently water soluble to be well absorbed. In addition 
very long chain esters are likely to exist as oils which would present 
formulation difficulties.
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Competitive inhibition of the glucuronic acid conjugation mechanism by the 
co-administration of other compounds sharing this pathway.
Supply of drugs ■ ■
Paracetamol and aspirin were obtained from Graesser Salicylates 
Limited, Sandycroft, Deerside, Flintshire. Salicylamide was purchased from 
Sigma Chemical Company Limited, London. Randomly tritiated meptazinol 
hydrochloride was supplied by the Medicinal Chemistry Department, Wyeth 
Laboratories (U.K.) ■ •
j '
Experimental design
•Z
H meptazinol hydrochloride was given orally to monkeys at 25 mg/kg 
either alone or in combination with paracetamol, aspirin or salicylamide at 
200 mg/kg, in a vehicle composed of 0.8^ carboxymethyl cellulose in isotonic 
saline. Heparinized blood samples i^ ere collected at various times after 
dosing. Unchanged meptazinol in the plasma was extracted by the method 
described in Chapter 2 and assayed by liquid scintillation counting.
Results and Discussions
The results presented in tables 3 5 ^ and 5 and fig. 2 show that 
combination of meptazinol with these minor analgesics produced no improvement 
in the plasma levels of the drug. Maximum plasma concentration of free 
meptazinol did not exceed 38 ng/ml, similar or even higher plasma levels 
having been previously seen after giving the drug alone. There was no 
evidence of saturation of the conjugation mechanism as indicated by the 
unchanged ratio of drug to glucuronide.
Paracetamol, aspirin and salicylamide did not appear to compete 
with meptazinol for the glucuronic acid conjugation mechanism. It is 
possible that the dose was not high enough to cause saturation but as this 
was already 200 mg/kg any further increase would seem impracticable. An 
alternative explanation is that the glucuronyl transferase responsible for the 
conjugation of meptazinol is quite specific and these other compounds would 
therefore not compete. A third possibility is that these compounds do not
undergo conjugation with glucuronic acid in the monkey as they do in man 
but may be sulphated. In this event they would not compete with meptazinol 
for the glucuronic acid conjugation mechanism.
Plasma levels of total radioactivity and radioactivity 
due to unchanged meptazinol in the monkey after oral 
administration of the drug (25 mg/kg) given alone or in
combination with aspirin, salicylamide or paracetamol 
(200 mg/kg)_______  ,_______________ ;________ __
0.05r TOLUENE EXTRACTABLE MATERIAL 100 TOTAL RADIOACTIVITY.
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Approach 3
Stimulation of gastric emptying by co-administration of metoclopramide. 
Experimental design
Three monkeys, starved overnight, received metoclopramide (Maxolon' 
obtained from Beecham Laboratories, Brentford, U.K.) intramuscularly the 
following morning at 2 mg/kg. Immediately afterwards they were dosed 
orally with meptazinol hydrochloride at 25 mg/kg. Heparinized blood 
samples were taken at various times up to 7 h after dosing. Unchanged 
meptazinol was extracted from the plasma as described in Chapter 2 and 
assaye^i by scintillation counting. • '
Results and Discussion
Absorption of meptazinol appeared to be more rapid when given with 
metoclopramide than when given alone(see fig. 3 and table 6). This was 
evidenced by peak total tritium levels in the plasma occurring by 1.5 h 
after dosing with the combination compared to 2-3.5 h when meptazinol was 
given alone. This increase in absorption rate probably reflects the 
stimulation of gastric emptying by metoclopramide.
Despite this increase in absorption rate, the plasma levels of 
unchanged meptazinol were not significantly higher than when meptazinol was 
given alone. The rate of absorption v/as apparently still not rapid enough 
to achieve plasma levels similar to those seen after direct instillation 
of the :drug into the duodenum. Increasing the dose of metoclopramide in 
an attempt to further stimulate gastric emptying would seem impracticable 
since marked central depressant activity including extra-pyrimidal side 
effects were seen after the dose used in the present study.
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Eectal Administration of the drug 
Preparation of suppositories
Suppositories of meptazinol hydrochloride were prepared by 
Mrs. S. Andruszko, Product Development Department, Wyeth Laboratories (U.K.). 
A.suspension of randomly tritiated meptazinol hydrochloride was made in 
Witepsol W^5*» a wax base composed of glycerides of natural saturated fatty 
acids. The molten suspension was poured into 1 g. moulds (H.B. Anden 
& Co.Ltd., Sittingbourne) and allowed to cool. For studies in the monkey 
each suppository contained 87.5 mg .meptazinol hydrochloride = 5.775m Ci.
For investigations in human volunteers each suppository contained 50 mg 
meptazinol hydrochloride = 75}* Ci.
Studies in monkeys
One male and one female monkey were given suppositories containing,
•2
H meptazinol at a dose of 25 mg/kg. Heparinized blood samples were 
collected at various times up to 7 h after dosing. Unchanged drug was 
extracted from the plasma as.previously described and subsequently assayed 
by liquid scintillation counting.
^Manufactured by Dynamit Nobel of Germany and supplied through Chemicals 
Trading Co.Ltd., London.
Studies in human volunteers
Two healthy human subjects, one male and one female, agreed to 
participate in this study. Neither subject had any history of haemorrhoids 
or any other abnormality of the lower bowel. The experimental design 
involved a comparative cross-over study in which each subject took 50 mg 
meptazinol = 75^ Ci tritium orally or rectally. Before taking the oral 
dose each subject fasted overnight and then, after swallowing the capsule, 
refrained from eating for the next 2-3 h'. Before inserting the suppository 
each subject was asked to empty their bowels. Heparinized blood samples 
(20 ml) were taken at various times afterwards and urine was collected up 
to ^8h after dosing.
Ini order to optimize the sensitivity of assay of free meptazinol, 
in plasma b ml aliquots were extracted with 15 ml of toluene scintillant 
after basification to pH9-5- 12 ml of the organic phase was subsequently
removed for liquid scintillation counting. ?
Results and Discussion
The results clearly demonstrate that rectal administration 
produces very much more rapid absorption than when the drug is given orally. 
In the monkey peak plasma levels after rectal administration were seen 
after only 0.5h (see fig. k & tables 7 & 8). By contrast after oral 
administration maximum plasma concentrations were not observed until 2.5 - 
3-5 h after dosing. Associated with this more rapid absorption after 
rectal dosage were considerably higher plasma levels of free drug and a 
lower proportion of conjugated material. Thus after rectal administration 
of 25 mg/kg to the monkey peak drug levels ranged from 150-300 ng/ml compared 
to only 15 - -^0 ng/ml after oral administration of the same dosage.
A similar picture emerged in the human (see fig.5)® ~After rectal
administration of 50 mg of the drug,peak plasma levels were achieved 
within 0.5 h of dosing compared to 1-2 h after oral administration (see 
table 9). (For comparative purposes additional data obtained in four other 
volunteers who took 50 mg of the radiolabelled drug orally is presented, 
see table 10). Peak plasma levels after 50 mg taken rectally were 53 
and 192 ng/ml compared to<20 ng/ml after oral administration at the same 
dosage. Absorption after rectal administration was not only rapid but also 
near complete as evidenced by the good urinary recovery of administered 
radioactivity (see tables 11 & 12). Between 65-90^ of the administered 
dose was recovered in the urine of the two volunteers who took the drug 
rectally^ similar amounts to those found after oral dosage.
At least two factors may be responsible for the elevated level 
of free meptazinol seen after rectal administration. Firstly rectal dosage 
would result in part of the dose being absorbed directly into the systemic
circulation through the inferior haemorrhoidal veins. In so doing this 
part of the dose would avoid the first pass effect in the liver. Secondly 
rectal administration circumvents the problem of slow gastric emptying, 
and absorption, as observed, is rapid. A consequence of this rapid 
absorption may be saturation of the glucuronic acid conjugating mechanism 
leading to higher plasma levels of the free drug;
The relative contribution of each of these factors remains a 
matter for speculation. However it is interesting to note that plasma 
levels produced by introduction of the same dosage into another part of the 
G.I. tract viz. duodenum (which would not result in drug entry directly into 
the systemic circulation) were similar to those produced a.fter rectal dosage. 
This v/ould tend to suggest that the contribution of the drug entry directly 
into the systemic circulation was very small.
General Discussion
Several different approaches have been investigated with the view 
of trying to reduce the extensive first pass conjugation responsible for the 
low oral potency of meptazinol. Only rectal administration has proved to be 
a practical solution to the problem. In addition to the improvement in 
potency there are several other potential advantages to a suppository 
formulation which should^ perhaps be mentioned. A number of patients have 
complained of the bitter metallic taste of meptazinol tablets, and rectal 
administration would therefore eliminate this problem. Furthermore 
suppositories may prove useful to patients who find difficulty in swallowing 
tablets. The rapidity of absorption of this suppository formulation of the 
drug would appear to offer a considerable advantage for an analgesic since 
severe pain clearly demands immediate relief. From the commercial view­
point too, the improvement in potency coupled with the very simple 
suppository formulation should make it an economic proposition.
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Fig.k.
Plasma levels of unchanged drug and total radioactivity 
'following rectal or oral administration of H Meptazinol 
at 2 5 mg/kg to two monkeys.
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or oral administration of 50 mg Meptazinol to tivo human volunteers.
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Table 11. Urinary recovery of radioactivity after oral or rectal dosage
3
of 30 nig H meptazinol to a male and to a female volunteer
Collection Period Subject
Pral
Dosage
J . Xj «
Rectal
Dosage
Subject
Oral
Dosage
G. J.
Rectal
Dosage
0 - 2 4 60.30# 87.47# 89.67# 38.82#
24 - 48 '1.62# 2.27# 1.96# 3.86#
Total 62.12# 89.74# ’ 91.63# 64.68#
Table 12. Urinary recovery of radioactivity after oral dosage of 
3
30mg H to four male volunteers.
Collection Period Subject R.B. Subject D.R. Subject C.W. Subject D.B.
0 - 2 4 67.31 39.67 60.87 38.87
2 4 - 4 8 0.91 0.88 0.64 1.03
Total 68.42 60.33 "" 61.31 39-92
Results expressed as # administered radioactivity
CHAPTER 9
A REVIEW OF THE ROLE OF DRUG METABOLISM STUDIES 
IN THE DEVELOPMENT OF MEPTAZINOL.
The investigations carried out to date represent an attempt to 
apply the study of drug metabolism and pharmacokinetics to the development 
of this new analgesic.
(a) Studies on the biotransformation of the compound
These studies have shown that the initial concern over the. 
possibility that the drug would undergo demethylation to what appeared to 
be a more addictive compound was unjustified. By the novel use of dual 
labelling it was shown that none of the species investigated, including 
rats, monkeys and man, significantly demethylated the compound with the 
exception of the male rat. The sex difference in the rat is particularly 
noteworthy since the female of the species totally lacked the ability to 
demethylate the compound. More usually sex difference are a matter of 
varying extents of a process that occurs in both sexes. (Such a sex 
difference Strongly supports the view that biological testing must be 
carried out in both sexes.)
N~demethylation, however,•even in male rats was only a relatively 
minor route of metabolism, the major route of biotransformation in all species 
so far examined being the rapid conjugation of the drug with glucuronic 
acid. In monkey and man an additional metabolite^was found which constituted 
3-10# of the dose. The identification of this minor metabolite was facili­
tated by the use of dual labelling. Comparative thin layer chromatography 
and infra red spectroscopy v/ith 6-ethyl-6-(m-hydroxyphenyl)-1-methylhexahydro- 
azepin-(2H)-2~one indicated that this metabolite was the result of oxidation 
at the 7 position in the azepine ring, the position where tritium had been 
specifically inserted in the molecule. Determination of the tritium/radio- 
carbon ratio in this metabolite indicated nearly total loss of tritium 
providing confirmation that reaction had taken place at this position. The 
chromatographic properties of this minor metabolite suggested that it was 
more lipophilic than meptazinol itself and might thus readily penetrate
nervous system depressants such as methsuximide and N-methyl glutethimide it 
was thought possible that it might possess some biological activity. However 
pharmacological evaluation showed it to have no interesting biological 
activity. Nevertheless this does demonstrate one potential area of the 
commercial application of drug metabolism studies. Had all or part of the 
biological activity of meptazinol resided in this metabolite then these 
studies v/ould have enabled patent protection to be sought with the view to 
developing a better drug.
(b) Studies on the relationship between the biological activity and plasma/ 
tissue concentration of the drug.
Extensive investigations in rats and monkeys showed a correlation 
between plasma and tissue levels of the free drug and the intensity of 
analgesia. Thus the poor analgesic response and lower toxicity of meptazinol 
seen after oral administration of the drug to monkeys was associated with 
very much lowrer plasma concentrations of the free drug than were seen in the 
rat. Furthermore in the rat a direct correlation between intensity of 
analgesia and plasma concentration of free meptazinol was demonstrated. 
Assuming a similar correlation to exiist between analgesia and plasma levels 
in man the most appropriate dosage regimen can now; be designed on the basis
of the kinetic behaviour of the drug in this species.
(c) Absorption kinetics of meptazinol and its implications
In the early stages of the drug's development a relatively low
oral potency of the drug in monkeys compared to rats and mice was noted
which prompted an investigation into the rate and extent of the absorption
of the compound in various species including man. The results showed that
while the drug was nearly completely absorbed in all species the rate of
attainment of peak blood levels (an indirect indication of absorption rate)
was much slower in monkeys and man compared to rats and mice. At this
stage data was available on the drug's analgesic activity after oral dosage
to man. This showed it to resemble the monkey more than the rat in its
oral potency.-
emptying rate played a significant role in this slow absorption. Thus when 
the drug was instilled directly into the duodenum, using a permanently 
implanted duodenal cannula absorption was very much more rapid than that 
following intragastric administration. Peak plasma drug concentrations 
were achieved more rapidly and were much higher than those resulting from 
intragastric dosing. Further studies showed that not only was the process 
of gastric emptying much, slower in this species than in the rat but that it 
was also significantly retarded by the action of the drug. These observations 
seem to provide a plausible explanation for the species difference in oral
i .
potenc^ of the drug. In the rat where stomach emptying time was short and 
unaffected by the drug (t-J, 9min) absorption proceeded rapidly. As a 
consequence of this, saturation of the conjugating mechanism probably occurred 
and relatively high concentrations of the free drug were therefore achieved.
In monkeys and man stomach emptying is intrinsically much slower than in the 
rat (tj monkey = 30 min, t-J man = 4-7 min.). In addition, in the monkey at 
least,' gastric emptying was retarded by the action of the drug. This slower 
stomach emptying and absorption may in consequence permit more extensive 
metabolism which would result in lower plasma levels of the unchanged drug.
Based on this understanding of the factors influencing plasma 
concentrations of the drug it was thought that perhaps rectal administration, 
by avoiding gastric emptying, would produce good plasma levels of the free 
drug. Studies in monkeys showed that giving the drug per rectum produced 
plasma levels similar to those seen after intraduodenal dosage i.e. 3 to 10 
times higher than after oral administration of the same dose. Later studies 
in human revealed a similar picture.
These observations on the influence of gastric emptying on the 
extent of the first pass conjugation of meptazinol may also be relevant to 
other phenolic analgesics which exert an inhibitory effect on gastric 
emptying. For example the relatively weak oral potency of pentazocine may 
conceivably be explained in similar terms. The drug is known to inhibit 
gastric emptying (Danhof et al 1966) and is subject to extensive first pass
however, suggests that rectal administration would not.provide a solution in 
this case since plasma levels after rectal dosage were no higher than after 
oral administration. This may have .been due to the intrinsically poorer 
absorption of this compound^ pKa 9»7f and to the nature of the suppository 
base.
Future metabolic studies on meptazinol in relation to its further development 
(1) Development of a more economic oral formulation of the drug.
As a result of these metabolic studies a suppository formulation 
of meptazinol is currently being evaluated in the clinic. Useful though 
this formulation may prove to be^  the major objective still remains to find 
a more economic oral formulation of the drug. In view of the benefit to 
be gained from more rapid absorption, it may be possible to design an oral 
formulation which delivers the drug as a bolus to its site of absorption i.e. 
the small intestine. This could be achieved by the use of enteric coated 
tablets or capsules. With such a formulation one of the most important 
factors would be the.rapidity of disintegration/dissolution once in the 
small intestine (for insufficiently rapid disintegration would lead to slow 
absorption and correspondingly low plasma levels). This might be achieved 
by inclusion of a swelling agent such as starch which would absorb moisture 
and eventually burst the capsule. A similar result could also be accomplished 
by the use of tartaric acid/sodium bicarbonate mixtures which would generate 
CO^ and eventually cause explosion of the capsule.. This principle has, in 
fact, been successfully employed in the anti-ulcer product ’duogastrone’ 
where local action on the duodenum is required.
An alternative means of producing rapid absorption of the drug 
might be to facilitate gastric absorption of the drug. As a weak base 
meptazinol would normally exist in the stomach in the ionized form, which 
would be insufficiently lipophilic to be well absorbed. However gastric 
absorption might be facilitated by the application of the "ion pair" 
absorption concept. Higuchi (19&7) proposed a mechanism to explain the
absorption of compounds which are entirely ionized at all physiological 
pH's such as the quaternary ammonium compounds and sulphonic acid.
According to Schanker's pH partition theory it is usually only the 
unionized more lipophilic form of the drug which is absorbed. Higuchi
suggested that absorption of quaternary ammonium compounds took place 
following combination with a suitable bulky anion which would effectively 
bury the charges of the two species. The resultant 'ion pair' might be 
sufficiently lipophilic to be absorbed by simple diffusion. Irwin et al 
(1969) examined this hypothesis using the quaternary ammonium compound 
isopropamide. They showed that the absorption of this compound could be
I!
very significantly enhanced by the formation of an 'ion. pair' with trich- 
loroacetate.
In the case of meptazinol it may be possible to achieve more 
rapid absorption by facilitating gastric absorption of the drug by formation 
of a suitable 'ion pair'.
2. Development of an improved intramuscular formulation of the drug
Another future area of involvement of metabolic studies is the 
development of meptazinol,lies in the modification of the intramuscular 
formulation. Since the compound has only a short plasma half life (2 h) 
relatively large doses of the drug have to be given to prolong the dosage, 
interval. By so doing however, plasma concentrations well above the 
minimum analgesic concentration may be achieved which might be responsible 
for side effects of nausea and vomiting seen in some patients. Although 
the real half life of elimination cannot be changed v/ithout recourse to 
molecular modification, the apparent half life could be extended by delaying 
its absorption from the site of injection. Preliminary studies in rats 
have shown that when the drug is given intramuscularly as the free base 
in arachis oil the half life can be increased by 100#. This concept of 
sustained release formulation for intramuscular injection has been used 
successfully for a wide variety of drugs. For example Julou et al'(1973)
reported on the extended duration of action of some long chain fatty acid
esters of the neuroleptic pipothiazine. The undecylenic ester had a duration
of action of about two weeks and that .of the palmitate about four weeks 
/ ' 
after subcutaneous administration. These esters appeared to be only slowly
released from the site of injection whence they were hydrolyzed back to
the active drug. A further example of a sustained release formulation is
that of naltrexone zinc tannate given in peanut oil. This narcotic
antagonist complex has a duration of action extending over several days
compared to just a few hours for the simple hydrochloride salt (Gray &
Robinson, 1974).
Thus a sustained release preparation of meptazinol such as long 
chain fatty acid esters given in an oil might well avoid the problems 
incurred by prolonging the duration of action through giving relatively high 
doses of the drug. -
3. Correlation of biological response in humans with plasma levels 
of the drug
Although a good correlation between analgesia and plasma levels of 
the drug has been demonstrated in animals, the existance of a similar 
relationship in man needs to be confirmed. This investigation would 
perhaps be best conducted in patients suffering real pain in view of the 
limitations of experimentally induced pain (see Chapter 1). However 
attempting to correlate pain relief with plasma drug levels in patients who 
may have hepatic or renal impairment in addition to suffering from various 
types of pain obviously presents its own difficulties. ' A compromise 
solution may be found in subjects undergoing pneumoencephalography. This 
involves injection of air intra-ventricularly into the brain and forms part 
of a radiographical diagnostic technique for brain tumours. The procedure 
is particularly painful requiring the administration of analgesics. Although 
this represents an experimentally induced form of pain and should therefore 
be fairly reproducible the subject has no control over it and the psycho­
logical component of real .pain is therefore present. ' Thus this may be a 
*The duration of action of unesterified pipothiazine was approximately 24
useful model for correlating pain relief with plasma drug levels.
In addition to establishing the plasma concentration associated 
with analgesia the levels observed in subjects reporting side effects such 
as nausea and vomiting should be established. Assuming a proportional 
relationship between the intensity of the drug's biological effects and 
plasma concentrations of the drug this should then enable the most 
appropriate dosage regimen to be designed.
Since it has been suggested that there exists a breakthrough 
dosage i.e. one at which the glucuronic acid conjugating mechanism becomes 
saturated, the relationship between dose and plasma concentration will noti "
be one of simple proportionality. In the region of the breakthrough 
dosage small increases in dose may be expected to produce disproportionately 
large increases in plasma concentration of the free drug. This relationship 
needs to be investigated for-each of the different routes of administration. 
Inter and intra subject variation in plasma levels achieved should also be 
determined.
4. Studies on microsomal enzyme induction.
Many drugs, on repeated administration may increase their own 
rate of elimination by causing hepatic microsomal enzyme induction. Clearly 
in such an instance, increasing doses of the drug would be required to 
maintain the same therapeutic response and this necessarily makes drug 
prescription more complex. However the problems associated with such drugs 
do not end there, for these compounds usually accelerate not only their 
own metabolism but also that of other drugs and in some cases endogenous 
compounds. Such drug interactions make prescribing even more difficult 
when one drug may affect the elimination of another. Furthermore deficiency 
conditions could arise through the enhanced metabolism of vital endogenous 
compounds over a prolonged period. For example the disorders of calcium 
metabolism and frank osteomalacia seen in some epileptic patients have 
been attributed to enzyme induction by anticonvulsant drugs which accelerate
metabolism of vitamin D (Hunter et al 1971)• Furthermore folate 
deficiency found in epileptic patients on anticonvulsant drugs was 
significantly related to increased hepatic microsomal enzyme activity 
and also correlated well with the daily dose of anticonvulsants taken 
(Maxwell et al 1972).
Although other analgesics such as morphine and pethidine are 
not reported to cause significant enzyme induction (Remmer, 1969)1 studies 
to ascertain whether meptazinol induces increased microsomal enzyme 
activity are clearly warranted in view of the adverse effects this 
property may confer. *
Concluding remarks
The objective of this thesis has been to demonstrate the use­
fulness of metabolic studies to drug research and development with 
particular reference to the new analgesic meptazinol. It is hoped that 
these studies have shown that there is more to be gained from drug 
metabolism than a mere recital of the identity of the biotransformation 
products of the compound. In the case of meptazinol the application 
of drug metabolism studies has enabled important questions very relevant 
to the future of the compound to be answered; questions concerning its 
absorption, its possible biotransformation to the more addictive desmethyl 
compound and the reasons for its relatively low oral potency. As a 
result of this biochemical understanding of the factors governing the drug1 
behaviour, the development of the compound has been furthered and the 
design of possible solutions to the problem of its low oral potency, 
facilitated.
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PRELIMINARY METABOLIC STUDIES 
ON THE NEW ANALGESIC MEPTAZINOL
M eptazinol, w -(3 -e th y l- l-m e th y l hexahydro-1 I I -  
azepin-3-y l) phenol hydrochloride (F igure 1) has 
been shown to possess potent analgesic activ ity  in 
rats, mice and m onkeys (G oode &  W h ite , 1971). 
Recent clinical studies have dem onstrated that the 
com pound is capable o f relieving severe pain in 
man (O osterlinck &  De Sy, 1975).
Prelim inary m etabolic studies have now been 
carried out in human volunteers who took drug 
labelled w ith  both radiocarbon and tritiu m . The  
m aterial was labelled w ith  [ l4C] on the N m e th y l, 
function  and [ 3 H ] on the 7 position in the 
azepine ring. This provided a convenient and 
sensitive way o f investigating the extent o f N 
dem ethylation , a like ly  route o f m etabolism  for 
this com pound.
Fight healthy male volunteers each swallowed a 
gelatin capsule containing 5 0 p C i [ 14C] and 
150 pC i [ 3 H 1 m eptazinol hydrochloride at doses 
ranging from  5 0 -200  mg. Blood samples and urine  
collections were taken at regular intervals during  
the first 24 h a fte r dosing. Faecal, samples were 
collected daily. A liquots o f plasma and urine were 
subjected d irectly  to  liquid scintillation  counting  
while faecal samples were homogenized and small 
samples digested prior to counting by the method  
o f M ahin &  Lofberg (1 9 6 6 ) .
As shown by the a tta inm ent o f peak plasma 
levels o f rad ioactivity  w ith in  1-2 h o f dosing, 
absorption o f the drug from  the gastrointestinal 
tract was rapid (Tab le  1). Furtherm ore, absorption  
appeared to  be near com plete as shown by the 
negligible amounts o f rad ioactivity  in the faeces 
( <  5.0% ) and the concom itantly  good recovery o f  
rad ioactivity  in the urine. Fxcretion  was very 
rapid, approxim ately  50%  o f the adm inistered  
rad ioactivity  appearing in the urine between 0-6 h 
after dosing. U rinary excretion was virtually  
com plete w ith in  24 hours.
The very sim ilar recovery o f both tritiu m  and 
radiocarbon indicated that N dem ethylation  did 
not occur to any significant extent ( Table 2). The  
m ajor m etabolite o f the drug appeared to be the 
glucuronide conjugate o f the parent drug. A  m inor 
m etabolite am ounting to 5-10%  o f the adm inis­
tered dose was observed to contain very little  
tr it iu m , suggesting that reaction had occurred at 
the 7 position o f the azepine ring. C om ­
parative th in  layer chrom atography o f this 
m etabo lite  w ith  6 - e thyl - 6 - (/// - h yd ro xyph eny lj
- 1 - m ethylhexahydro  - azepin - (2111 * 2-- one 
showed the tw o com pounds to behave very sim i­
larly . Isolation o f larger am ounts o f this m inor 
m etabolite from  the urine o f tw o further volun­
teers who had ingested 1.2 g o f the drug enabled 
the infra-red spectrum to  be determ ined. Again the 
m inor m etabolite and the 7 oxo com pound  
appeared to be very similar. These data, together 
w ith  a report o f a structurally  similar m etabolite  
o f the closely related analgesic profadol (Chang, 
1 9 6 8 ), provides substantial evidence to  identify  
the m inor m etabolite o f m eptazinol as 6 - ethyl - 6 - 
(m - h yd ro xyph eny l) -1  - m ethylhexahydro  - azepin
- [211] - 2 - one.
A comprehensive report o f this work w ill be 
presented -in due course.
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Drug Metabolism Section, Wyeth laboratories, 
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Figure 1 Structural formula of meptazinol hydro­
chloride with the asterisks showing the location of the 
radioisotopes.
c2h5 
H CI
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Table 1 Plasma levels of total radiocarbon in male 
volunteers following ingestion of radiolabelled 
meptazinol
Time after Doseof meptazinol(mg)dosing (h) 50* 100** 200**
0.25 0.05 no sample no sample
0.50 0.55 2.95 1.89
1.00 1.39 5.24 6.56
2.00 1.23 4.20 6.74
3.00 0.86 2.90 4.92
4.00 0.56 1.85 3.78
6.00 0.33 1.25 2.12
8.00 0.25 0.84 1.54
12.00 0.17 0.59 1.08
24.00 0.12 0.29 0.53
48.00 no sample 0.17
Results expressed as pg equivalents meptazinol HCI/ml 
plasma
* mean vaiue from four subjects 
**  mean value from two subjects.
T545-BJCP-LE 2033-2
Table 2 Urinary excretion of radioactivity by male volunteers after ingestion of radiolabelled meptazinol
Collection 50* Dose of meptazinol (mg) 100** 200**period (h) lwC/'H] r'C/'H) ["C/'H]
0-3 39.53/34.13 40.84/34.42 24.43/21.73
3-6 17.30/16.98 24.19/22.73 34.03/29.68
6-9 5.43/5.35 7.23/7.78 | 14.30/14.149-12 1.98/2.22')
12-15 1.10/1.35 J- 6.91/7.84 1.83/2.09
15-24 1.03/1.70 J 0.98/1.21
24-48 0.38/0.87 1.24/2.55 0.58/1.24
48-72 0.06/0.94 0.11/0.60
Totals 66.75/62.60 80.47/75.86 76.26/70.69
All results expressed as % administered dose 
* mean value from four subjects 
• •  mean value from two subjects.
